https://gvhdhub.com daily 1 2026-04-03T21:04:50.741Z https://gvhdhub.com/types weekly 0.8 2025-03-26T12:15:00.000Z https://gvhdhub.com/types/graft-versus-host-disease weekly 0.7 2025-08-22T08:03:00.000Z https://gvhdhub.com/types/acute-graft-versus-host-disease weekly 0.7 2025-08-19T12:36:00.000Z https://gvhdhub.com/types/chronic-graft-versus-host-disease weekly 0.7 2025-08-19T12:36:00.000Z https://gvhdhub.com/types/gi-agvhd-1 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/types/risk weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics weekly 0.8 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/antibody-therapy weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/immunosuppressants weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/cellular-therapy weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/rock-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/calcineurin-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/chemotherapy weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/biological-therapy weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/jak-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/microbiota-therapy weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/steroid-refractory-gvhd-1 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/mtor-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/btk-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/protease-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/proteasome-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/immune-modulators weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/other-1 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/hdac-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/antifibrotic weekly 0.7 2025-11-05T15:51:00.000Z https://gvhdhub.com/therapeutics/nuclear-receptor-agonists weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/antibiotics weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/dpp-4-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/bcl-2-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/terminase-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/hypomethylating-agents weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/endothelial-protection weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/chemokine-receptor-antagonists weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/therapeutics/syk-inhibitors weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses weekly 0.8 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses/ash weekly 0.7 2026-01-12T16:23:00.000Z https://gvhdhub.com/congresses/ebmt weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses/iach-2019 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses/other weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses/eha weekly 0.7 2025-07-03T10:03:00.000Z https://gvhdhub.com/congresses/costem weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses/soho weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses/asco weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses/tct-meetings weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses/aacr weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/congresses/iach weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials weekly 0.8 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/rockstar weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/precision-t weekly 0.7 2025-04-17T14:23:00.000Z https://gvhdhub.com/trials/abc weekly 0.7 2026-03-12T14:42:00.000Z https://gvhdhub.com/trials/agave-201 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/ares weekly 0.7 2025-07-11T12:45:00.000Z https://gvhdhub.com/trials/chronos weekly 0.7 2026-03-12T14:43:00.000Z https://gvhdhub.com/trials/reach5 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/idunn weekly 0.7 2025-04-04T13:24:00.000Z https://gvhdhub.com/trials/balder weekly 0.7 2025-11-05T14:59:00.000Z https://gvhdhub.com/trials/access weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/thrive weekly 0.7 2025-12-03T17:16:00.000Z https://gvhdhub.com/trials/equator weekly 0.7 2025-12-03T17:15:00.000Z https://gvhdhub.com/trials/bmt-ctn-1703 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/reach3 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/reach2 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/allg-bm12-cast weekly 0.7 2025-07-30T08:41:00.000Z https://gvhdhub.com/trials/graphite weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/phoebus weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/hamlet weekly 0.7 2025-06-25T15:06:00.000Z https://gvhdhub.com/trials/rockreal weekly 0.7 2025-05-08T12:09:00.000Z https://gvhdhub.com/trials/rocknrol-1 weekly 0.7 2025-04-29T15:33:00.000Z https://gvhdhub.com/trials/stargaze weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/real-greffe weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/phylos weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/octet-ever weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/magic weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/heracles weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/alxn1007 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/reach1 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/aba2 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/neutrodiet weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/gravitas-309 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/irene-g weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/equate weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/bmt-ctn-1101 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/kd025-208 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/bmt-ctn-1301 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/gvhd-1 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/gvhd-2 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/odyssee weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/gmed16-001 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/bmt-ctn-1202 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/anzhit-1 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/gravitas-301 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/alpha weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/balance weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/able-cgvhd weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/bmt-ctn-1501 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/trials/bmt-ctn-1203 weekly 0.7 2025-03-26T12:15:00.000Z https://gvhdhub.com/expert-opinions weekly 0.8 2025-03-27T09:28:00.000Z https://gvhdhub.com/drug-updates weekly 0.8 2025-03-27T09:28:00.000Z https://gvhdhub.com/educational-resources weekly 0.8 2026-01-19T15:49:00.000Z https://gvhdhub.com/educational-resources/spotlights weekly 0.7 2025-11-19T13:34:00.000Z https://gvhdhub.com/educational-resources/visual-abstracts weekly 0.7 2025-11-19T13:34:00.000Z https://gvhdhub.com/educational-resources/steering-committee-meetings weekly 0.7 2025-11-19T13:34:00.000Z https://gvhdhub.com/educational-resources/e-learning weekly 0.7 2026-01-19T15:36:00.000Z https://gvhdhub.com/educational-resources/gvhd-hub-symposiums weekly 0.7 2025-11-19T13:34:00.000Z https://gvhdhub.com/educational-resources/editorial-themes weekly 0.7 2025-12-19T12:43:00.000Z https://gvhdhub.com/educational-resources/drug-approvals weekly 0.7 2025-11-19T13:34:00.000Z https://gvhdhub.com/educational-resources/infection weekly 0.7 2025-03-31T12:20:00.000Z https://gvhdhub.com/educational-resources/supportive-care weekly 0.7 2025-03-31T12:20:00.000Z https://gvhdhub.com/educational-resources/diagnostic-and-treatment-guidelines weekly 0.7 2026-01-19T15:36:00.000Z https://gvhdhub.com/medical-information/atg-vs-alemtuzumab-based-gvhd-prophylaxis-in-ric-allo-hsct-for-all monthly 0.9 2026-04-02T16:00:00.000Z https://gvhdhub.com/medical-information/allo-hsct-outcomes-in-aya-patients-with-acute-leukemia monthly 0.9 2026-04-02T08:42:00.000Z https://gvhdhub.com/medical-information/european-commission-grants-conditional-marketing-authorization-to-belumosudil-for-cgvhd monthly 0.9 2026-04-01T12:44:00.000Z https://gvhdhub.com/medical-information/ptcy-based-gvhd-prophylaxis-after-hla-matched-allo-hsct-in-pediatric-and-aya-patients monthly 0.9 2026-03-31T16:00:00.000Z https://gvhdhub.com/medical-information/response-dynamics-to-belumosudil-rockstar-ad-hoc-analysis monthly 0.9 2026-03-31T14:49:00.000Z https://gvhdhub.com/medical-information/ebmt-2026-live-congress-coverage-from-the-gvhd-hub monthly 0.9 2026-04-02T11:49:00.000Z https://gvhdhub.com/medical-information/ebmt-2026-congress-coverage-acute-gvhd monthly 0.9 2026-03-30T14:39:00.000Z https://gvhdhub.com/medical-information/ebmt-2026-congress-coverage-chronic-gvhd monthly 0.9 2026-03-30T14:39:00.000Z https://gvhdhub.com/medical-information/reach5-final-analysis-ruxolitinib-in-pediatric-treatment-naivesteroid-refractory-cgvhd monthly 0.9 2026-03-26T15:55:00.000Z https://gvhdhub.com/medical-information/real-world-outcomes-of-belumosudil-for-treatment-refractory-cgvhd-italian-experience monthly 0.9 2026-03-26T10:00:00.000Z https://gvhdhub.com/medical-information/ebmt-2026-top-abstracts-whats-hot-in-gvhd monthly 0.9 2026-03-18T16:33:00.000Z https://gvhdhub.com/medical-information/proposed-diagnostic-scoring-system-for-pnsm-cgvhd monthly 0.9 2026-03-19T11:04:00.000Z https://gvhdhub.com/medical-information/bioprevent-machine-learning-algorithm-using-post-transplant-biomarkers-to-predict-cgvhd-and-nrm monthly 0.9 2026-03-17T09:48:00.000Z https://gvhdhub.com/medical-information/real-world-outcomes-of-belumosudil-in-treatment-refractory-cgvhd monthly 0.9 2026-03-12T14:00:00.000Z https://gvhdhub.com/medical-information/ptcy-vs-tac-based-regimens-for-cutaneous-sclerotic-cgvhd-prophylaxis monthly 0.9 2026-03-27T11:34:00.000Z https://gvhdhub.com/medical-information/correlation-between-plasma-biomarkers-and-post-allo-hsct-complications-in-pediatric-patients monthly 0.9 2026-03-05T12:10:00.000Z https://gvhdhub.com/medical-information/real-world-treatment-patterns-or-ecp-in-sr-gvhd-a-delphi-study monthly 0.9 2026-03-03T16:01:00.000Z https://gvhdhub.com/medical-information/de-escalated-ptcy-ruxolitinib-for-gvhd-prophylaxis monthly 0.9 2026-03-03T11:15:00.000Z https://gvhdhub.com/medical-information/belumosudil-ecp-in-cgvhd-rockstar-post-hoc-analysis monthly 0.9 2026-02-26T13:00:00.000Z https://gvhdhub.com/medical-information/real-world-outcomes-of-belumosudil-in-pediatric-and-young-adult-patients-with-cgvhd monthly 0.9 2026-02-25T11:00:00.000Z https://gvhdhub.com/medical-information/mscs-as-an-alternative-to-ruxolitinib-real-world-use-of-msc-ffm-in-agvhd monthly 0.9 2026-02-25T12:19:00.000Z https://gvhdhub.com/medical-information/whartons-jelly-mscs-in-high-risk-and-sr-agvhd-phase-ib-trial-results monthly 0.9 2026-02-20T15:08:00.000Z https://gvhdhub.com/medical-information/ptcy-vs-standard-gvhd-prophylaxis-in-matched-donor-allohsct monthly 0.9 2026-02-18T11:37:00.000Z https://gvhdhub.com/medical-information/what-are-the-treatment-options-for-chronic-gvhd-associated-fibrosis monthly 0.9 2026-03-05T17:37:00.000Z https://gvhdhub.com/medical-information/nih-consensus-task-force-refined-response-criteria-for-cutaneous-cgvhd monthly 0.9 2026-02-13T12:58:00.000Z https://gvhdhub.com/medical-information/2026-tandem-meetings-congress-coverage-chronic-gvhd monthly 0.9 2026-02-11T11:05:00.000Z https://gvhdhub.com/medical-information/2026-tandem-meetings-congress-coverage-acute-gvhd monthly 0.9 2026-02-11T11:05:00.000Z https://gvhdhub.com/medical-information/2026-tandem-meetings-live-congress-coverage-from-the-gvhd-hub monthly 0.9 2026-02-11T11:04:00.000Z https://gvhdhub.com/medical-information/mscs-from-clinical-trials-to-clinical-practice monthly 0.9 2026-02-26T11:06:00.000Z https://gvhdhub.com/medical-information/outcomes-of-flumel-conditioning-tacsir-gvhd-prophylaxis-in-allo-hsct-in-aml monthly 0.9 2026-02-10T16:22:00.000Z https://gvhdhub.com/medical-information/e-learning-module-ecp-for-the-treatment-of-gvhd-best-practice-guidelines monthly 0.9 2026-02-04T17:04:00.000Z https://gvhdhub.com/medical-information/ema-recommends-conditional-marketing-authorization-for-belumosudil-for-cgvhd monthly 0.9 2026-02-04T14:19:00.000Z https://gvhdhub.com/medical-information/ecp-in-the-treatment-of-acute-and-chronic-gvhd-guided-case-studies monthly 0.9 2026-02-04T14:26:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-ecp-for-sr-gvhd monthly 0.9 2026-02-02T15:32:00.000Z https://gvhdhub.com/medical-information/donor-selection-for-allo-hsct-nmdpcibmtr-guidelines monthly 0.9 2026-01-28T12:00:00.000Z https://gvhdhub.com/medical-information/guidelines-and-recommendations-for-the-use-of-ecp-in-the-treatment-of-gvhd monthly 0.9 2026-02-04T14:26:00.000Z https://gvhdhub.com/medical-information/clinical-data-supporting-ecp-in-the-treatment-of-gvhd monthly 0.9 2026-02-04T14:26:00.000Z https://gvhdhub.com/medical-information/ebmt-consensus-recommendations-for-atgatlg-in-allo-hsct monthly 0.9 2026-01-23T17:22:00.000Z https://gvhdhub.com/medical-information/mscs-for-the-treatment-of-sr-agvhd monthly 0.9 2026-01-21T14:00:00.000Z https://gvhdhub.com/medical-information/overview-of-the-unmet-needs-in-gvhd-and-an-introduction-to monthly 0.9 2026-02-04T14:25:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-for-the-treatment-of-bos-after-allo-hsct monthly 0.9 2026-01-16T13:10:00.000Z https://gvhdhub.com/medical-information/precision-t-phase-iii-subgroup-analysis-orca-t-for-gvhd-prophylaxis monthly 0.9 2026-01-14T12:31:00.000Z https://gvhdhub.com/medical-information/real-world-symptom-burden-improvement-with-belumosudil-in-sr-cgvhd monthly 0.9 2026-01-09T12:42:00.000Z https://gvhdhub.com/medical-information/phase-i-trial-donor-derived-cd6-car-tregs-in-chronic-gvhd monthly 0.9 2026-01-07T16:37:00.000Z https://gvhdhub.com/medical-information/ares-phase-iii-maat013-for-ruxolitinib-refractory-acute-gvhd-with-gi-involvement monthly 0.9 2026-01-02T09:00:00.000Z https://gvhdhub.com/medical-information/rockstar-response-dynamics-to-belumosudil-in-cgvhd monthly 0.9 2025-12-29T12:00:00.000Z https://gvhdhub.com/medical-information/ptcy-vs-atg-for-gvhd-prophylaxis-in-810-hla-mmud-transplantation-an-ebmt-analysis monthly 0.9 2025-12-23T12:00:00.000Z https://gvhdhub.com/medical-information/long-term-outcomes-with-ruxolitinib-ecp-in-sr-agvhd monthly 0.9 2025-12-19T10:27:00.000Z https://gvhdhub.com/medical-information/ash-2025-live-congress-coverage-from-the-gvhd-hub monthly 0.9 2025-12-23T15:21:00.000Z https://gvhdhub.com/medical-information/ash-2025-congress-coverage-acute-gvhd monthly 0.9 2025-12-16T09:01:00.000Z https://gvhdhub.com/medical-information/ash-2025-congress-coverage-gvhd-prophylaxis monthly 0.9 2025-12-16T09:01:00.000Z https://gvhdhub.com/medical-information/cryopreserving-mncs-for-ecp-in-pediatric-patients-with-steroid-resistant-gvhd monthly 0.9 2025-12-11T12:00:00.000Z https://gvhdhub.com/medical-information/ash-2025-top-abstracts-whats-hot-in-gvhd monthly 0.9 2025-12-03T17:33:00.000Z https://gvhdhub.com/medical-information/what-are-the-treatment-options-for-ruxolitinib-refractory-acute-gvhd monthly 0.9 2025-12-01T15:50:00.000Z https://gvhdhub.com/medical-information/symposium-series-guidance-vs-practice-how-can-we-improve-treatment-of-sr-gvhd monthly 0.9 2025-11-25T16:00:00.000Z https://gvhdhub.com/medical-information/symposium-early-treatment-strategies-for-sr-gvhd monthly 0.9 2025-12-05T17:42:00.000Z https://gvhdhub.com/medical-information/real-world-outcomes-of-belumosudil-in-sr-cgvhd-canadian-compassionate-use-program monthly 0.9 2025-11-24T14:35:00.000Z https://gvhdhub.com/medical-information/symposium-quality-of-life-and-symptoms-in-cgvhd monthly 0.9 2025-12-03T16:31:00.000Z https://gvhdhub.com/medical-information/low-dose-ptcy-alemtuzumab-for-gvhd-prevention monthly 0.9 2025-11-20T13:00:00.000Z https://gvhdhub.com/medical-information/symposium-the-importance-of-real-world-data-in-allogeneic-stem-cell-transplantation-a-focus-on-cgvhd monthly 0.9 2025-11-27T13:52:00.000Z https://gvhdhub.com/medical-information/rgi-2001-for-agvhd-prophylaxis-results-from-a-phase-iib-trial monthly 0.9 2025-11-14T14:47:00.000Z https://gvhdhub.com/medical-information/biomarkers-for-optimizing-ecp-treatment-for-acute-and-chronic-gvhd monthly 0.9 2025-11-13T09:19:00.000Z https://gvhdhub.com/medical-information/what-are-the-current-treatment-options-for-steroid-refractory-chronic-gvhd monthly 0.9 2025-11-14T13:33:00.000Z https://gvhdhub.com/medical-information/stop-bos-phase-i-trial-of-pirfenidone-for-bos-related-to-cgvhd monthly 0.9 2025-11-06T13:00:00.000Z https://gvhdhub.com/medical-information/mscs-in-gvhd-and-key-msc-ffm-safety-data monthly 0.9 2025-11-05T15:29:00.000Z https://gvhdhub.com/medical-information/reach2-final-analysis-ruxolitinib-vs-bat-in-sr-agvhd monthly 0.9 2025-11-03T12:41:00.000Z https://gvhdhub.com/medical-information/mscs-in-pediatric-sr-gvhd-after-allo-hsct monthly 0.9 2025-10-29T14:21:00.000Z https://gvhdhub.com/medical-information/nccn-guidelines-for-allo-hsct-and-management-of-gvhd-version-32025 monthly 0.9 2025-11-03T12:42:00.000Z https://gvhdhub.com/medical-information/real-world-outcomes-of-belumosudil-in-steroid-refractory-cgvhd monthly 0.9 2025-10-22T12:00:00.000Z https://gvhdhub.com/medical-information/managing-pulmonary-cgvhd-post-hsct-a-stepwise-approach monthly 0.9 2025-10-15T11:55:00.000Z https://gvhdhub.com/medical-information/what-are-the-major-challenges-in-the-treatment-of-sr-gvhd-and-how-can-clinicians-overcome-these monthly 0.9 2025-10-16T14:45:00.000Z https://gvhdhub.com/medical-information/iach-2025-live-congress-coverage-from-the-gvhd-hub monthly 0.9 2025-10-14T11:26:00.000Z https://gvhdhub.com/medical-information/ratgatlg-improves-outcomes-in-msd-allo-hsct-an-ebmt-registry-study monthly 0.9 2025-10-08T13:01:00.000Z https://gvhdhub.com/medical-information/biomarkers-for-risk-of-chronic-gvhd-by-age-group monthly 0.9 2025-10-07T09:51:00.000Z https://gvhdhub.com/medical-information/day-28-refined-response-criteria-for-acute-gvhd-a-jstct-and-magic-study monthly 0.9 2025-10-03T08:10:00.000Z https://gvhdhub.com/medical-information/joint-consensus-from-the-tbmt-and-tspccm-on-pulmonary-cgvhd monthly 0.9 2025-10-01T16:11:00.000Z https://gvhdhub.com/medical-information/real-world-outcomes-of-belumosudil-results-from-the-rockreal-study monthly 0.9 2025-09-26T10:57:00.000Z https://gvhdhub.com/medical-information/impact-of-donor-age-on-allo-hsct-outcomes-a-cibmtr-registry-study monthly 0.9 2025-09-24T14:45:00.000Z https://gvhdhub.com/medical-information/mmf-dose-optimization-for-gvhd-prophylaxis-in-ucbt monthly 0.9 2025-09-18T16:19:00.000Z https://gvhdhub.com/medical-information/magic-composite-response-integration-of-clinical-and-biomarker-data-to-predict-long-term-agvhd-outcomes monthly 0.9 2025-09-12T15:25:00.000Z https://gvhdhub.com/medical-information/gvhd-impact-on-haplo-hsct-with-ptcy-outcomes-in-all-a-retrospective-ebmt-registry-study monthly 0.9 2025-09-10T09:46:00.000Z https://gvhdhub.com/medical-information/ptcy-atg-vs-ptcy-alone-for-gvhd-prophylaxis-in-haplo-hsct-a-retrospective-ebmt-registry-study monthly 0.9 2025-09-01T14:56:00.000Z https://gvhdhub.com/medical-information/ixazomib-as-chronic-gvhd-prophylaxis-findings-from-a-phase-ii-trial monthly 0.9 2025-08-27T10:44:00.000Z https://gvhdhub.com/medical-information/rls-0071-pegtarazimod-granted-orphan-drug-designation-by-the-ema monthly 0.9 2025-08-22T15:01:00.000Z https://gvhdhub.com/medical-information/msc-treatment-for-patients-with-sr-agvhd-long-term-results-from-a-phase-iii-trial monthly 0.9 2025-08-18T14:00:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-for-steroid-refractory-or-steroid-dependent-chronic-gvhd-3-year-final-analysis-of-the-reach3-trial monthly 0.9 2025-08-07T10:30:00.000Z https://gvhdhub.com/medical-information/key-findings-from-a-retrospective-study-investigating-ruxolitinib-ecp-in-sr-agvhd monthly 0.9 2025-08-07T11:48:00.000Z https://gvhdhub.com/medical-information/the-phase-iii-allg-bm12-cast-trial-gvhd-prophylaxis-with-ptcy-plus-csa monthly 0.9 2025-07-31T10:32:00.000Z https://gvhdhub.com/medical-information/post-hoc-analysis-of-the-graphite-phase-iii-trial-vedolizumab-for-lower-gi-agvhd-prophylaxis-in-japanese-patients monthly 0.9 2025-07-24T08:35:00.000Z https://gvhdhub.com/medical-information/maat013-in-steroid-refractory-and-steroid-dependent-gi-agvhd-outcomes-from-an-early-access-program-and-the-phase-iii-ares-trial monthly 0.9 2025-07-30T10:36:00.000Z https://gvhdhub.com/medical-information/a-2025-update-from-the-working-groups-of-nih-chronic-gvhd-consensus-conference monthly 0.9 2025-07-11T15:07:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-with-tocilizumab-in-combination-with-csa-and-mmf-in-cord-blood-transplantation-a-phase-ii-trial monthly 0.9 2025-07-08T09:55:00.000Z https://gvhdhub.com/medical-information/how-can-measurement-of-qol-and-use-of-pros-be-improved-in-cgvhd monthly 0.9 2025-07-10T14:19:00.000Z https://gvhdhub.com/medical-information/eha-2025-congress-coverage-gvhd-prophylaxis monthly 0.9 2025-06-25T15:01:00.000Z https://gvhdhub.com/medical-information/eha-2025-live-congress-coverage monthly 0.9 2025-06-27T10:21:00.000Z https://gvhdhub.com/medical-information/ecp-ruxolitinib-to-prevent-cgvhd-in-patients-with-sr-agvhd monthly 0.9 2025-07-02T18:14:00.000Z https://gvhdhub.com/medical-information/effect-of-ptcy-for-gvhd-prophylaxis-on-ocular-gvhd monthly 0.9 2025-06-19T14:05:00.000Z https://gvhdhub.com/medical-information/kinetics-of-chimerism-and-outcomes-after-gvhd-prophylaxis-with-ptcy-vs-mtx-post-hsct monthly 0.9 2025-06-06T15:43:00.000Z https://gvhdhub.com/medical-information/eha-2025-abstracts-whats-hot-in-gvhd monthly 0.9 2025-06-06T15:37:00.000Z https://gvhdhub.com/medical-information/real-world-outcomes-of-belumosudil-compared-with-best-available-therapy-results-from-the-rockreal-study monthly 0.9 2025-07-28T08:41:00.000Z https://gvhdhub.com/medical-information/transplant-outcomes-with-alternative-donors-in-mf-a-japanese-registry-analysis monthly 0.9 2025-06-03T10:35:00.000Z https://gvhdhub.com/medical-information/high-dose-palifermin-for-gvhd-prophylaxis-results-from-a-phase-iii-trial monthly 0.9 2025-05-27T13:12:00.000Z https://gvhdhub.com/medical-information/msc-infusion-for-gvhd-prophylaxis-post-haplo-hsct monthly 0.9 2025-05-20T09:21:00.000Z https://gvhdhub.com/medical-information/addition-of-peri-transplant-ruxolitinib-to-sirolimus-and-tacrolimus-for-gvhd-prophylaxis-in-patients-with-mf-undergoing-allo-hct monthly 0.9 2025-05-13T16:12:00.000Z https://gvhdhub.com/medical-information/real-world-safety-and-efficacy-of-belumosudil-results-from-the-rockreal-trial monthly 0.9 2025-06-03T09:42:00.000Z https://gvhdhub.com/medical-information/how-does-real-world-evidence-complement-rcts-and-why-is-it-important-for-small-patient-populations monthly 0.9 2025-05-08T12:37:00.000Z https://gvhdhub.com/medical-information/real-world-use-of-belumosudil-key-insights-and-future-perspectives monthly 0.9 2025-04-30T14:00:00.000Z https://gvhdhub.com/medical-information/safety-and-efficacy-of-human-amniotic-epithelial-stem-cell-eye-drops-for-ocular-cgvhd monthly 0.9 2025-04-25T09:24:00.000Z https://gvhdhub.com/medical-information/abatacept-ptcy-and-bortezomib-combination-for-gvhd-prophylaxis monthly 0.9 2025-04-23T10:44:00.000Z https://gvhdhub.com/medical-information/precision-t-a-phase-iii-trial-of-orca-t-vs-soc-for-cgvhd-prophylaxis-in-advanced-hematologic-malignancies monthly 0.9 2025-04-17T14:51:00.000Z https://gvhdhub.com/medical-information/co-occurrence-of-inflammation-and-fibrosis-in-cgvhd monthly 0.9 2025-04-08T15:12:00.000Z https://gvhdhub.com/medical-information/key-insights-into-mscs-for-agvhd-the-current-clinical-trial-landscape monthly 0.9 2025-05-08T13:04:00.000Z https://gvhdhub.com/medical-information/results-from-a-phase-iii-trial-of-rovadicitinib-for-srsd-cgvhd monthly 0.9 2025-04-04T07:58:00.000Z https://gvhdhub.com/medical-information/51st-ebmt-annual-meeting-live-congress-feed monthly 0.9 2025-04-23T12:27:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-in-adult-and-pediatric-steroid-refractory-gvhd-long-term-real-world-outcomes monthly 0.9 2025-03-27T15:25:00.000Z https://gvhdhub.com/medical-information/51st-annual-meeting-of-the-ebmt-congress-coverage-cgvhd monthly 0.9 2025-04-23T12:27:00.000Z https://gvhdhub.com/medical-information/atg-vs-atlg-as-gvhd-prophylaxis-following-allo-hsct monthly 0.9 2025-03-21T07:52:00.000Z https://gvhdhub.com/medical-information/51st-annual-meeting-of-the-ebmt-congress-coverage-gvhd-prophylaxis monthly 0.9 2025-04-23T12:15:00.000Z https://gvhdhub.com/medical-information/phylos-trial-ptcy-as-gvhd-prophylaxis-after-mismatched-unrelated-hct monthly 0.9 2025-03-20T12:11:00.000Z https://gvhdhub.com/medical-information/prevalence-of-viral-infection-and-reactivation-over-10-years-of-hsct-in-pediatric-patients monthly 0.9 2025-03-13T10:28:00.000Z https://gvhdhub.com/medical-information/impact-of-obesity-on-gvhd-risk-after-allo-hct monthly 0.9 2025-03-06T16:35:00.000Z https://gvhdhub.com/medical-information/association-between-vitamins-a-d-e-and-k-and-the-risk-of-gvhd-post-transplant monthly 0.9 2025-03-05T11:01:00.000Z https://gvhdhub.com/medical-information/jaki-throughout-hct-reduces-rates-of-agvhd monthly 0.9 2025-02-26T14:50:00.000Z https://gvhdhub.com/medical-information/outcomes-in-older-vs-younger-patients-undergoing-pbsct-with-ptcy monthly 0.9 2025-02-18T09:59:00.000Z https://gvhdhub.com/medical-information/2025-tandem-meetings-or-transplantation-and-cellular-therapy-meetings-of-astct-and-cibmtr monthly 0.9 2025-04-03T13:13:00.000Z https://gvhdhub.com/medical-information/decreasing-rates-of-cgvhd-in-all-patient-populations-post-hsct monthly 0.9 2025-02-13T15:14:00.000Z https://gvhdhub.com/medical-information/belumosudil-for-cgvhd-3-year-follow-up-from-the-rockstar-trial monthly 0.9 2025-02-13T09:16:00.000Z https://gvhdhub.com/medical-information/knowgvhd-call-to-action monthly 0.9 2025-02-14T14:55:00.000Z https://gvhdhub.com/medical-information/co-infusion-of-mscs-during-hsct-for-gvhd-prophylaxis monthly 0.9 2025-02-05T16:51:00.000Z https://gvhdhub.com/medical-information/real-world-effectiveness-of-msc-ffm-in-ruxolitinib-refractory-agvhd monthly 0.9 2025-07-15T14:51:00.000Z https://gvhdhub.com/medical-information/cgvhd-answering-the-unanswered monthly 0.9 2025-08-05T14:11:00.000Z https://gvhdhub.com/medical-information/how-should-we-be-measuring-gvhd-qol-in-clinical-practice monthly 0.9 2025-08-05T14:12:00.000Z https://gvhdhub.com/medical-information/apraglutide-for-sr-agvhd-results-from-the-phase-ii-stargaze-trial monthly 0.9 2025-01-23T10:11:00.000Z https://gvhdhub.com/medical-information/impact-of-dietary-fiber-on-gvhd-outcomes-in-pre-clinical-models-and-patients-receiving-allo-hsct monthly 0.9 2025-01-16T17:24:00.000Z https://gvhdhub.com/medical-information/bmt-ctn-1703-post-hoc-analysis-ptcy-based-gvhd-prophylaxis-in-older-patients monthly 0.9 2025-01-16T17:19:00.000Z https://gvhdhub.com/medical-information/low-dose-ruxolitinib-reduces-incidence-of-agvhd-post-haplo-hsct monthly 0.9 2025-01-08T15:57:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-with-donor-lymphocyte-infusion-in-patients-treated-with-ptcy monthly 0.9 2024-12-20T10:40:00.000Z https://gvhdhub.com/medical-information/fda-approves-remestemcel-l-for-the-treatment-of-pediatric-patients-with-sr-agvhd monthly 0.9 2025-07-21T10:51:00.000Z https://gvhdhub.com/medical-information/2024-ash-annual-meeting-live-congress-feed monthly 0.9 2025-04-03T13:39:00.000Z https://gvhdhub.com/medical-information/ash-2024-abstracts-what-s-hot-in-gvhd monthly 0.9 2024-12-02T09:55:00.000Z https://gvhdhub.com/medical-information/ibrutinib-in-patients-with-steroid-refractory-cgvhd-results-from-a-real-world-analysis monthly 0.9 2024-11-28T16:43:00.000Z https://gvhdhub.com/medical-information/multidisciplinary-management-of-cgvhd-post-hsct monthly 0.9 2024-11-27T13:38:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-plus-corticosteroids-in-newly-diagnosed-patients-with-agvhd-results-from-a-phase-iii-trial monthly 0.9 2024-11-13T15:39:00.000Z https://gvhdhub.com/medical-information/highlights-from-the-cgvhd-symposium monthly 0.9 2024-11-13T12:11:00.000Z https://gvhdhub.com/medical-information/machine-learning-based-analysis-of-the-impact-of-donor-characteristics-on-post-hct-outcomes monthly 0.9 2024-11-07T10:48:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-in-combination-with-belumosudil-for-patients-with-treatment-refractory-cgvhd monthly 0.9 2024-11-06T11:26:00.000Z https://gvhdhub.com/medical-information/um171-expanded-cord-blood-transplantation-for-patients-with-high-risk-ndmm-results-from-a-phase-iii-trial monthly 0.9 2024-10-31T13:12:00.000Z https://gvhdhub.com/medical-information/comparison-of-three-gvhd-prophylaxis-regimens-post-haplosct monthly 0.9 2024-10-28T16:39:00.000Z https://gvhdhub.com/medical-information/impact-of-mait-cell-recovery-on-outcomes-in-pediatric-and-young-adult-patients-undergoing-allo-hsct monthly 0.9 2024-10-25T08:58:00.000Z https://gvhdhub.com/medical-information/cgvhd-symposium-2024-live-congress-feed monthly 0.9 2025-04-03T13:25:00.000Z https://gvhdhub.com/medical-information/impact-of-race-ethnicity-and-socioeconomic-status-on-outcomes-in-patients-with-gvhd monthly 0.9 2024-10-18T10:44:00.000Z https://gvhdhub.com/medical-information/an-update-of-italian-best-practice-recommendations-for-ecp-use-in-gvhd monthly 0.9 2024-10-03T10:50:00.000Z https://gvhdhub.com/medical-information/axatilimab-for-cgvhd-results-from-the-phase-ii-agave-201-trial monthly 0.9 2024-10-01T15:07:00.000Z https://gvhdhub.com/medical-information/iach-2024-live-congress-feed monthly 0.9 2024-10-01T14:50:00.000Z https://gvhdhub.com/medical-information/optimal-dosing-of-mmf-with-ptcy-in-patients-undergoing-haploidentical-pbsct monthly 0.9 2024-09-26T11:17:00.000Z https://gvhdhub.com/medical-information/interventional-antibiotic-treatment-vs-systemic-antibiotic-prophylaxis-in-patients-undergoing-allo-hsct monthly 0.9 2024-09-20T08:39:00.000Z https://gvhdhub.com/medical-information/acute-and-chronic-gvhd-an-overview monthly 0.9 2025-12-19T11:40:00.000Z https://gvhdhub.com/medical-information/addition-of-atg-to-standard-prophylaxis-reduces-incidence-of-acute-and-chronic-gvhd monthly 0.9 2024-09-18T15:56:00.000Z https://gvhdhub.com/medical-information/impact-of-donor-age-and-type-in-patients-with-aml-undergoing-allo-hsct monthly 0.9 2024-09-05T14:48:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-for-treatment-of-sclerotic-cgvhd-results-from-a-phase-ii-study monthly 0.9 2026-03-06T14:59:00.000Z https://gvhdhub.com/medical-information/ecp-for-the-treatment-of-cgvhd-emerging-data-and-clinical-management-considerations monthly 0.9 2025-07-15T14:54:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-in-pediatric-patients-with-chronic-gvhd-interim-results-from-reach5 monthly 0.9 2024-09-05T13:26:00.000Z https://gvhdhub.com/medical-information/prophylactic-gvhd-treatment-with-atlg-in-patients-with-myelofibrosis monthly 0.9 2024-08-29T14:39:00.000Z https://gvhdhub.com/medical-information/ptcy-as-a-prophylaxis-regimen-for-patients-with-hodgkin-lymphoma monthly 0.9 2024-08-22T14:21:00.000Z https://gvhdhub.com/medical-information/rls-0071-granted-orphan-drug-designation-and-fast-track-designation-by-the-u-s-fda monthly 0.9 2024-08-22T13:15:00.000Z https://gvhdhub.com/medical-information/management-of-drug-related-adverse-events-in-patients-with-steroid-refractory-cgvhd monthly 0.9 2025-05-20T10:59:00.000Z https://gvhdhub.com/medical-information/infection-prophylaxis-for-patients-with-gvhd monthly 0.9 2025-08-05T08:57:00.000Z https://gvhdhub.com/medical-information/fda-approves-axatilimab-for-the-treatment-of-cgvhd monthly 0.9 2025-07-21T10:50:00.000Z https://gvhdhub.com/medical-information/vedolizumab-for-the-prevention-of-lower-gi-agvhd-results-from-a-phase-iii-trial monthly 0.9 2024-08-13T12:06:00.000Z https://gvhdhub.com/medical-information/future-perspectives-of-ecp-for-gvhd-treatment monthly 0.9 2024-08-19T12:47:00.000Z https://gvhdhub.com/medical-information/ptcy-and-short-term-everolimus-as-gvhd-prophylaxis-results-from-the-phase-ii-octet-ever-trial monthly 0.9 2024-08-06T14:48:00.000Z https://gvhdhub.com/medical-information/ptcy-based-gvhd-prophylaxis-following-mmud-peripheral-blood-stem-cell-transplantation-results-from-the-phase-ii-access-trial monthly 0.9 2024-07-31T10:10:00.000Z https://gvhdhub.com/medical-information/symposium-or-early-intervention-and-use-of-ecp-combinations-in-cgvhd monthly 0.9 2025-08-05T08:55:00.000Z https://gvhdhub.com/medical-information/belumosudil-in-japanese-patients-with-cgvhd-results-from-a-phase-iii-trial monthly 0.9 2024-07-17T16:01:00.000Z https://gvhdhub.com/medical-information/symposium-or-ecp-for-chronic-gvhd-patient-eligibility-treatment-optimization-and-follow-up monthly 0.9 2025-08-05T08:54:00.000Z https://gvhdhub.com/medical-information/atg-and-ptcy-monotherapy-vs-combination-therapy-for-agvhd-prophylaxis monthly 0.9 2024-07-15T16:26:00.000Z https://gvhdhub.com/medical-information/symposium-or-the-long-term-burden-of-cgvhd monthly 0.9 2025-08-05T08:54:00.000Z https://gvhdhub.com/medical-information/symposium-or-a-brief-overview-and-history-of-ecp monthly 0.9 2025-08-05T08:54:00.000Z https://gvhdhub.com/medical-information/mini-dose-methotrexate-plus-methylprednisolone-for-patients-with-agvhd-results-from-a-phase-iii-trial monthly 0.9 2024-07-01T09:41:00.000Z https://gvhdhub.com/medical-information/eha2024 monthly 0.9 2024-07-01T09:41:00.000Z https://gvhdhub.com/medical-information/ucb-derived-platelet-gel-for-the-treatment-of-skin-ulcers-in-pediatric-patients-with-cgvhd-results-from-a-randomized-trial monthly 0.9 2024-06-19T09:06:00.000Z https://gvhdhub.com/medical-information/prediction-of-response-and-long-term-outcomes-of-second-line-therapy-for-patients-with-agvhd-a-magic-analysis monthly 0.9 2024-06-12T08:25:00.000Z https://gvhdhub.com/medical-information/effects-of-antibiotic-exposure-following-allo-hct-with-non-myeloablative-flu-tbi-conditioning monthly 0.9 2024-05-15T14:44:00.000Z https://gvhdhub.com/medical-information/the-addition-of-tacrolimus-to-treg-graft-for-gvhd-prophylaxis monthly 0.9 2024-05-10T08:16:00.000Z https://gvhdhub.com/medical-information/impact-of-clostridioides-difficile-infection-and-its-treatment-on-allo-hsct-outcomes monthly 0.9 2024-04-29T12:47:00.000Z https://gvhdhub.com/medical-information/association-of-treatment-sensitive-dependent-and-resistant-chronic-gvhd-with-clinical-outcomes monthly 0.9 2024-04-23T14:30:00.000Z https://gvhdhub.com/medical-information/impact-of-cd34-cell-dose-on-patient-outcomes-after-haplo-pbsct-with-ptcy monthly 0.9 2024-04-22T12:35:00.000Z https://gvhdhub.com/medical-information/the-use-of-patient-reported-outcomes-as-a-prognostic-marker-in-cutaneous-cgvhd monthly 0.9 2024-03-28T15:12:00.000Z https://gvhdhub.com/medical-information/ecp-clinical-considerations-for-the-treatment-of-cgvhd monthly 0.9 2024-05-08T11:54:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-a-retrospective-comparison-of-ptcy-and-atg-combinations monthly 0.9 2024-03-27T16:02:00.000Z https://gvhdhub.com/medical-information/dual-t-cell-depletion-for-gvhd-prophylaxis-in-adults-post-haplo-hct monthly 0.9 2024-03-26T10:35:00.000Z https://gvhdhub.com/medical-information/the-use-of-ptcy-for-gvhd-prophylaxis-in-adults-post-hsct-data-from-a-phase-ii-trial monthly 0.9 2024-03-26T11:03:00.000Z https://gvhdhub.com/medical-information/the-use-of-day-14-endpoint-models-in-agvhd-clinical-trials monthly 0.9 2024-03-21T16:58:00.000Z https://gvhdhub.com/medical-information/biomarkers-and-risk-factors-in-flares-of-agvhd-magic-analysis monthly 0.9 2024-03-19T16:31:00.000Z https://gvhdhub.com/medical-information/navigating-treatment-sequencing-of-cgvhd-real-world-insights monthly 0.9 2024-03-13T14:58:00.000Z https://gvhdhub.com/medical-information/dupilumab-in-recalcitrant-pediatric-atopic-dermatitis-like-graft-versus-host-disease-a-case-series monthly 0.9 2024-03-12T17:49:00.000Z https://gvhdhub.com/medical-information/updated-consensus-recommendations-from-the-ebmt-on-prophylaxis-and-management-of-post-transplant-graft-versus-host-disease monthly 0.9 2024-03-05T14:47:00.000Z https://gvhdhub.com/medical-information/effect-of-oral-chronic-gvhd-on-bodyweight-in-adults monthly 0.9 2024-03-01T14:28:00.000Z https://gvhdhub.com/medical-information/vitamin-a-pre-allo-hsct-for-the-prevention-of-gvhd-results-from-a-randomized-phase-ii-trial monthly 0.9 2025-10-01T16:18:00.000Z https://gvhdhub.com/medical-information/ecp-in-adult-patients-with-gvhd-a-real-world-experience monthly 0.9 2024-02-28T11:07:00.000Z https://gvhdhub.com/medical-information/safety-and-efficacy-of-low-dose-rituximab-in-steroid-refractory-cgvhd monthly 0.9 2024-02-08T16:29:00.000Z https://gvhdhub.com/medical-information/the-agave-201-trial-safety-and-efficacy-of-axatilimab-at-three-different-doses monthly 0.9 2024-01-29T12:01:00.000Z https://gvhdhub.com/medical-information/study-design-of-the-phase-ii-phoebus-trial-of-maat013 monthly 0.9 2024-01-25T11:33:00.000Z https://gvhdhub.com/medical-information/reach3-3-year-final-safety-and-efficacy-analysis monthly 0.9 2024-01-19T11:48:00.000Z https://gvhdhub.com/medical-information/sirolimus-vs-tacrolimus-in-gvhd-prophylaxis-following-haploidentical-allo-hct-a-retrospective-analysis monthly 0.9 2024-01-19T09:47:00.000Z https://gvhdhub.com/medical-information/usp17l-rna-in-immune-cells-a-potential-biomarker-in-gut-gvhd monthly 0.9 2024-01-12T17:05:00.000Z https://gvhdhub.com/medical-information/efficacy-of-hucb-mscs-as-a-salvage-therapy-for-sr-agvhd monthly 0.9 2023-12-15T16:12:00.000Z https://gvhdhub.com/medical-information/supportive-care-provision-for-patients-with-gvhd monthly 0.9 2025-08-05T08:57:00.000Z https://gvhdhub.com/medical-information/acute-graft-versus-host-disease-prophylactic-mitigation-via-novel-st2-inhibition monthly 0.9 2023-12-13T10:04:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-novel-strategies-and-future-directions monthly 0.9 2025-08-05T08:56:00.000Z https://gvhdhub.com/medical-information/visual-abstract-or-ruxolitinib-versus-basiliximab-in-adult-patients-with-steroid-refractory-agvhd monthly 0.9 2023-12-08T10:27:00.000Z https://gvhdhub.com/medical-information/ash-2023-abstracts-what-s-hot-in-gvhd monthly 0.9 2023-12-07T16:52:00.000Z https://gvhdhub.com/medical-information/outcomes-biomarkers-and-risk-factors-in-de-novo-late-agvhd monthly 0.9 2023-11-29T13:56:00.000Z https://gvhdhub.com/medical-information/impact-of-fungal-infections-on-transplant-outcomes-a-cibmtr-analysis monthly 0.9 2023-11-27T14:28:00.000Z https://gvhdhub.com/medical-information/novel-therapies-for-the-prevention-and-treatment-of-acute-gvhd monthly 0.9 2025-10-01T16:17:00.000Z https://gvhdhub.com/medical-information/effect-of-fluticasone-propionate-donor-cell-conditioning-on-the-incidence-and-severity-of-gvhd monthly 0.9 2023-11-02T11:02:00.000Z https://gvhdhub.com/medical-information/a-phase-ii-trial-of-cd24fc-for-gvhd-prophylaxis monthly 0.9 2023-10-19T12:54:00.000Z https://gvhdhub.com/medical-information/nutritional-interventions-in-acute-gvhd monthly 0.9 2023-10-09T11:45:00.000Z https://gvhdhub.com/medical-information/repurposing-drugs-for-gvhd-prevention-and-treatment monthly 0.9 2025-10-01T16:17:00.000Z https://gvhdhub.com/medical-information/visual-abstractor-pooled-allogeneic-faecal-microbiota-therapy-for-steroid-resistant-gi-agvhd monthly 0.9 2023-09-19T12:10:00.000Z https://gvhdhub.com/medical-information/significance-of-patient-and-transplant-factors-in-development-of-kidney-dysfunction-in-patients-with-cgvhd monthly 0.9 2023-12-04T10:04:00.000Z https://gvhdhub.com/medical-information/employment-income-and-caregiver-impact-of-cgvhd-after-hsct monthly 0.9 2025-10-01T16:15:00.000Z https://gvhdhub.com/medical-information/full-dose-mtx-tac-vs-mini-mtx-tacmmf-for-gvhd-prophylaxis monthly 0.9 2025-10-01T16:15:00.000Z https://gvhdhub.com/medical-information/significance-of-dby-hla-class-ii-complexes-in-cgvhd-development-post-hsct monthly 0.9 2025-10-01T16:14:00.000Z https://gvhdhub.com/medical-information/comparison-of-ptcy-based-gvhd-versus-standard-prophylaxis-regimen-in-patients-with-hematologic-malignancies monthly 0.9 2023-07-27T09:37:00.000Z https://gvhdhub.com/medical-information/positive-topline-results-from-the-agave-201-trial-of-axatilimab monthly 0.9 2023-07-25T14:13:00.000Z https://gvhdhub.com/medical-information/visual-abstract-or-reach5-ruxolitinib-in-pediatric-cgvhd monthly 0.9 2024-07-17T11:01:00.000Z https://gvhdhub.com/medical-information/is-the-novel-jakrock-inhibitor-tq05105-effective-for-patients-with-srsd-cgvhd monthly 0.9 2023-12-04T10:05:00.000Z https://gvhdhub.com/medical-information/a-phase-ii-trial-of-alxn1007-a-c5a-complement-inhibitor-for-use-in-lower-gi-agvhd monthly 0.9 2025-10-01T16:13:00.000Z https://gvhdhub.com/medical-information/prognostic-significance-of-clinical-patient-characteristics-and-blood-biomarkers-in-sr-and-sd-agvhd-reach2 monthly 0.9 2023-11-27T11:13:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-defining-steroid-and-ruxolitinib-refractory-acute-and-chronic-gvhd monthly 0.9 2024-07-17T11:16:00.000Z https://gvhdhub.com/medical-information/eha-2023 monthly 0.9 2023-06-12T07:42:00.000Z https://gvhdhub.com/medical-information/is-combination-atg-ptcy-prophylaxis-always-preferable-to-using-each-agent-separately-in-haplo-hct monthly 0.9 2023-11-27T11:14:00.000Z https://gvhdhub.com/medical-information/fecal-microbiota-transplantation-in-high-risk-lower-gi-acute-gvhd-after-allo-hct monthly 0.9 2023-05-18T12:43:00.000Z https://gvhdhub.com/medical-information/what-is-the-latest-data-from-reach-3-for-ruxolitinib-treated-patients-with-sr-cgvhd-after-crossover monthly 0.9 2023-11-27T11:12:00.000Z https://gvhdhub.com/medical-information/impact-of-gvhd-on-post-transplantation-outcomes-following-cbt-and-ptcy-haplo-hct-for-adult-aml monthly 0.9 2023-05-09T10:50:00.000Z https://gvhdhub.com/medical-information/case-study-or-therapy-refractory-chronic-gvhd monthly 0.9 2025-08-05T08:53:00.000Z https://gvhdhub.com/medical-information/impact-of-graft-cd4cd8-ratio-on-hsct-outcomes-with-different-gvhd-prophylaxis-regimens monthly 0.9 2023-05-02T15:53:00.000Z https://gvhdhub.com/medical-information/how-to-sequence-agents-for-steroid-refractory-chronic-gvhd monthly 0.9 2025-08-05T08:53:00.000Z https://gvhdhub.com/medical-information/is-vedolizumab-effective-for-preventing-lower-gi-acute-gvhd monthly 0.9 2023-04-26T09:08:00.000Z https://gvhdhub.com/medical-information/omidubicel-onlv-granted-fda-approval-for-patients-with-hematologic-malignancies-eligible-for-umbilical-cord-blood-transplantation monthly 0.9 2025-07-21T10:51:00.000Z https://gvhdhub.com/medical-information/ebmt-2023 monthly 0.9 2023-04-19T14:27:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-with-abatacept-in-mismatched-unrelated-donor-hct monthly 0.9 2023-04-04T13:23:00.000Z https://gvhdhub.com/medical-information/immunosuppressive-efficacy-and-safety-of-mscs-bioengineered-with-chimeric-antigen-receptor-car-in-gvhd-preclinical-models monthly 0.9 2023-03-24T12:59:00.000Z https://gvhdhub.com/medical-information/visual-abstract-or-vitamin-a-for-the-prevention-of-gvhd-in-pediatric-patients-undergoing-allo-hsct monthly 0.9 2024-07-17T11:01:00.000Z https://gvhdhub.com/medical-information/orca-t-in-patients-undergoing-allo-hsct-for-hematologic-malignancies monthly 0.9 2023-03-09T14:18:00.000Z https://gvhdhub.com/medical-information/a-validated-clinical-risk-score-to-predict-posttransplant-agvhd monthly 0.9 2023-02-27T15:43:00.000Z https://gvhdhub.com/medical-information/tct-2023 monthly 0.9 2023-02-09T14:43:00.000Z https://gvhdhub.com/medical-information/case-study-51-year-old-with-chronic-gvhd-with-no-improvement-after-a-week-on-prednisone monthly 0.9 2023-02-08T15:28:00.000Z https://gvhdhub.com/medical-information/baricitinib-use-in-patients-with-agvhd-receiving-hla-matched-pbsct monthly 0.9 2023-02-01T09:17:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-in-combination-with-low-dose-steroids-for-intermediate-and-high-risk-agvhd monthly 0.9 2023-01-26T16:02:00.000Z https://gvhdhub.com/medical-information/maat013-a-pooled-microbiota-therapy-for-the-treatment-of-gi-agvhd monthly 0.9 2023-01-16T16:21:00.000Z https://gvhdhub.com/medical-information/ptcy-tacrolimus-and-mycophenolate-mofetil-as-gvhd-prophylaxis monthly 0.9 2023-01-16T14:25:00.000Z https://gvhdhub.com/medical-information/the-protective-effect-of-leukemia-inhibitory-factor-against-gvhd-after-allo-bmt monthly 0.9 2023-01-10T15:37:00.000Z https://gvhdhub.com/medical-information/the-neutrodiet-trial-is-a-protective-diet-necessary-after-sct monthly 0.9 2023-01-09T16:38:00.000Z https://gvhdhub.com/medical-information/itacitinib-and-corticosteroids-for-chronic-gvhd monthly 0.9 2022-12-20T09:53:00.000Z https://gvhdhub.com/medical-information/what-should-supportive-care-look-like-for-patients-with-chronic-gvhd monthly 0.9 2024-07-17T12:02:00.000Z https://gvhdhub.com/medical-information/key-considerations-for-the-use-of-ecp-in-gvhd monthly 0.9 2025-08-05T08:56:00.000Z https://gvhdhub.com/medical-information/what-is-extracorporeal-photopheresis monthly 0.9 2025-08-05T08:55:00.000Z https://gvhdhub.com/medical-information/looking-to-the-future-of-ecp-for-the-management-of-gvhd monthly 0.9 2025-08-05T08:55:00.000Z https://gvhdhub.com/medical-information/editorial-theme-infection-prophylaxis-in-pediatric-and-adult-patients-receiving-hsct monthly 0.9 2022-12-14T16:17:00.000Z https://gvhdhub.com/medical-information/what-is-the-latest-update-on-the-gravitas-309-trial monthly 0.9 2022-12-14T15:36:00.000Z https://gvhdhub.com/medical-information/ash-congress-2022 monthly 0.9 2022-12-06T16:58:00.000Z https://gvhdhub.com/medical-information/comparison-of-endoscopic-and-histological-signs-of-agvhd-in-the-upper-gastrointestinal-tract monthly 0.9 2022-12-06T16:12:00.000Z https://gvhdhub.com/medical-information/ash-2022-abstracts-whats-hot-in-gvhd monthly 0.9 2023-03-27T14:34:00.000Z https://gvhdhub.com/medical-information/does-using-haplo-hsct-compared-with-cord-blood-transplant-impact-gvhd-rates monthly 0.9 2022-11-10T11:12:00.000Z https://gvhdhub.com/medical-information/the-safety-and-efficacy-of-fecal-microbiota-therapy-in-patients-with-gvhd monthly 0.9 2022-11-04T15:27:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-nutritional-support-for-improved-clinical-outcomes-post-hsct monthly 0.9 2024-07-17T11:17:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-irene-g-a-prospective-rct-of-nutritional-support-following-allo-hsct monthly 0.9 2022-10-28T15:46:00.000Z https://gvhdhub.com/medical-information/updated-guidelines-for-post-hsct-vaccination monthly 0.9 2024-07-17T15:25:00.000Z https://gvhdhub.com/medical-information/patient-and-physician-perceptions-of-palliative-care-during-transplant monthly 0.9 2022-11-23T11:19:00.000Z https://gvhdhub.com/medical-information/the-safety-and-efficacy-of-low-dose-interleukin-2-for-the-treatment-of-sr-cgvhd monthly 0.9 2022-09-26T14:52:00.000Z https://gvhdhub.com/medical-information/developments-in-ocular-gvhd monthly 0.9 2025-10-01T16:12:00.000Z https://gvhdhub.com/medical-information/use-of-ptcy-in-gvhd-prophylaxis-findings-from-a-prospective-and-a-retrospective-study monthly 0.9 2025-10-01T16:11:00.000Z https://gvhdhub.com/medical-information/patterns-of-liver-injury-and-cytokine-profiles-in-chronic-hepatic-gvhd-after-transplant-refining-current-nih-consensus-criteria monthly 0.9 2025-10-01T16:11:00.000Z https://gvhdhub.com/medical-information/new-biomarkers-for-the-diagnosis-and-prognosis-of-gvhd monthly 0.9 2025-10-01T16:10:00.000Z https://gvhdhub.com/medical-information/nih-consensus-task-force-on-atypical-chronic-gvhd-following-allo-hsct-new-diagnostic-criteria-and-future-research-prospects monthly 0.9 2022-08-18T13:17:00.000Z https://gvhdhub.com/medical-information/updated-results-from-a-phase-ib-and-phase-iii-trial-of-orca-t monthly 0.9 2022-08-15T15:24:00.000Z https://gvhdhub.com/medical-information/efficacy-of-early-repeated-infusion-of-mscs-in-gvhd-prophylaxis-after-haplo-hsct monthly 0.9 2022-07-28T08:03:00.000Z https://gvhdhub.com/medical-information/how-should-duration-of-response-be-defined monthly 0.9 2024-06-25T15:41:00.000Z https://gvhdhub.com/medical-information/how-should-novel-agents-be-used-in-the-current-treatment-pathways-for-gvhd monthly 0.9 2024-06-25T15:40:00.000Z https://gvhdhub.com/medical-information/how-to-optimize-donor-selection-for-allogeneic-transplant monthly 0.9 2022-07-07T13:34:00.000Z https://gvhdhub.com/medical-information/article-title-required-non-restrictive-diet-post-hsct-preliminary-analysis-of-phase-iii-prospective-trial-data-presented-at-eha2022 monthly 0.9 2022-07-06T15:05:00.000Z https://gvhdhub.com/medical-information/asco-2022 monthly 0.9 2022-09-02T08:38:00.000Z https://gvhdhub.com/medical-information/eha-2022 monthly 0.9 2022-08-01T11:05:00.000Z https://gvhdhub.com/medical-information/tandem-2022 monthly 0.9 2022-08-01T10:39:00.000Z https://gvhdhub.com/medical-information/what-is-the-role-of-human-beta-defensin-2-in-modulation-of-the-microbiome-and-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/safety-and-efficacy-of-axatilimab-in-patients-with-cgvhd-who-have-failed-2-lines-of-systemic-therapy monthly 0.9 2022-06-22T15:11:00.000Z https://gvhdhub.com/medical-information/abatacept-as-a-novel-agent-for-the-treatment-of-steroid-refractory-cgvhd-a-phase-ii-trial monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/findings-from-the-prospective-imagine-trial-of-ibrutinib-in-pediatric-patients-with-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/prevention-of-cgvhd-by-naive-t-cell-depletion monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-would-you-treat-agvhd-in-your-clinic-an-eu-perspective monthly 0.9 2022-05-12T08:14:00.000Z https://gvhdhub.com/medical-information/what-is-the-latest-update-on-biomarkers-for-assessing-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/validity-of-the-minnesota-agvhd-risk-score-in-predicting-survival-and-response-to-therapy monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-is-approved-by-the-european-commission-for-the-treatment-of-patients-with-sr-gvhd monthly 0.9 2025-07-21T10:51:00.000Z https://gvhdhub.com/medical-information/editorial-theme-t-cell-depletion-strategies-to-reduce-incidence-of-gvhd-in-pediatric-hsct-recipients monthly 0.9 2025-10-01T16:10:00.000Z https://gvhdhub.com/medical-information/preventing-gvhd-with-posttransplant-cyclophosphamide-combined-with-cyclosporin-a-results-from-hovon-96 monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/positive-interim-findings-from-the-equate-trial-including-the-mechanism-of-action-of-itolizumab-in-patients-with-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-should-supportive-care-look-like-for-patients-with-gvhd-what-role-does-physical-activity-play-in-these-patients monthly 0.9 2024-07-17T12:02:00.000Z https://gvhdhub.com/medical-information/how-do-we-stratify-risk-in-patients-with-gvhd monthly 0.9 2022-04-27T12:14:00.000Z https://gvhdhub.com/medical-information/how-does-gvhd-affect-outcomes-for-pediatric-patients-undergoing-allo-sct-for-all monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ebmt-2022 monthly 0.9 2022-08-01T10:50:00.000Z https://gvhdhub.com/medical-information/editorial-theme-genetic-predisposition-and-endoscopic-diagnosis-of-agvhd-in-pediatric-patients monthly 0.9 2024-07-17T11:17:00.000Z https://gvhdhub.com/medical-information/bowel-wall-thickness-with-transabdominal-ultrasound-as-a-predictive-tool-for-sr-agvhd-with-gut-involvement-after-allo-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/update-from-the-heracles-trial-and-expanded-access-program-of-maat013-in-patients-with-sr-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/mechanisms-of-action-of-ibrutinib-ruxolitinib-and-belumosudil-and-their-role-in-cgvhd-treatment monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/when-would-you-use-atg-vs-ptcy-for-gvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/supportive-care-requirements-of-patients-with-gvhd monthly 0.9 2024-07-17T12:02:00.000Z https://gvhdhub.com/medical-information/considerations-in-the-treatment-of-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/healthcare-inequalities-in-bone-marrow-transplants monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/rockstar-belumosudil-in-chronic-gvhd-an-update-from-ash-2021 monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-do-pre-allo-hsct-conditioning-regimens-impact-gvhd-outcomes-in-myelofibrosis-patients monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-might-itacitinib-prophylaxis-impact-haplo-hsct-outcomes-in-the-future monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/amphiregulin-as-a-biomarker-for-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-could-uhcgegf-fit-into-current-agvhd-treatment-pathways monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-is-failure-free-survival-impacted-by-belumosudil-in-cgvhd-which-has-failed-prior-therapy monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/phase-ii-trial-of-urinary-derived-human-chorionic-gonadotropinepidermal-growth-factor-for-the-treatment-of-agvhd-and-the-validation-of-amphiregulin-as-a-biomarker monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/haploidentical-donor-bloodmarrow-transplantation-with-ptcy-for-chronic-phase-myelofibrosis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/is-axatilimab-for-cgvhd-well-tolerated-and-what-does-the-preliminary-response-data-look-like monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/a-phase-iii-study-of-calcineurin-inhibitor-free-chronic-gvhd-prophylaxis-in-patients-undergoing-hla-matched-myeloablative-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/effectiveness-of-letermovir-prophylaxis-for-cmv-infection-in-patients-with-or-without-acute-gvhd monthly 0.9 2024-07-17T11:07:00.000Z https://gvhdhub.com/medical-information/ash-2022 monthly 0.9 2022-08-01T11:30:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-treatment-pre-during-and-post-transplant-for-patients-with-mf monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-s-the-latest-in-treatment-of-steroid-refractory-acute-gvhd-at-ash-2021 monthly 0.9 2022-01-27T15:08:00.000Z https://gvhdhub.com/medical-information/hla-mis-matching-in-haploidentical-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/developments-in-the-management-of-cgvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ser-155-for-the-treatment-of-patients-post-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/approval-of-abatacept-for-prophylactic-treatment-of-agvhd monthly 0.9 2025-07-21T10:49:00.000Z https://gvhdhub.com/medical-information/increased-risk-of-nrm-and-its-associated-factors-in-patients-with-chronic-gvhd-an-updated-analysis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/diverting-enterostomy-to-treat-steroid-resistant-gastrointestinal-acute-graft-versus-host-disease monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/peri-transplant-ruxolitinib-in-patients-with-myelofibrosis-a-phase-i-trial monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ash21-abstracts-what-s-hot-in-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/consensus-statements-for-pediatric-gvhd-recommendations-from-the-ebmt-transplant-complications-working-party monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/advances-in-the-prognosis-and-treatment-of-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-efficacy-and-safety-of-ofatumumab-plus-prednisone-in-cgvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-do-you-think-are-the-most-promising-new-drugs-in-the-treatment-of-steroid-refractory-cgvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-impact-of-non-classical-symptoms-of-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/post-transplant-maintenance-therapy-low-dose-decitabine-venetoclax-is-safe-and-effective-for-high-risk-aml-and-mds monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/comparison-of-posttransplant-outcomes-between-haploidentical-and-matched-unrelated-donor-recipients-receiving-ptcy-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/role-of-ampk-in-minimizing-gvhd-in-allogeneic-effector-t-cells monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/fda-approval-of-ruxolitinib-for-the-treatment-of-patients-with-chronic-gvhd monthly 0.9 2025-07-21T10:50:00.000Z https://gvhdhub.com/medical-information/an-overview-of-the-role-of-atg-in-preventing-acute-and-chronic-gvhd-after-allo-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ptcy-increased-infection-frequency-and-delayed-cd4-cell-reconstitution-but-faster-b-cell-reconstitution-vs-conventional-gvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-incidence-and-clinical-characteristics-of-liver-cgvhd-onset-during-calcineurin-inhibitor-tapering monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/developments-in-gvhd-prophylaxis-in-allogenic-stem-cell-transplantation-including-the-role-of-ptcy monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/severity-of-sars-cov-2-infection-and-the-safety-of-covid-19-vaccination-in-patients-receiving-hsct monthly 0.9 2025-10-01T16:09:00.000Z https://gvhdhub.com/medical-information/management-of-steroid-refractory-chronic-graft-versus-host-disease monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/microbiota-dynamics-and-prediction-of-agvhd-post-allo-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/gvhd-management monthly 0.9 2024-07-17T15:25:00.000Z https://gvhdhub.com/medical-information/fungal-superinfections-and-covid-19-in-the-icu monthly 0.9 2025-10-01T16:08:00.000Z https://gvhdhub.com/medical-information/rag1-co-expression-signature-identifies-a-novel-subset-of-etv6-runx1-like-bcp-all-in-pediatric-patients monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ifn-therapy-and-recombinant-il-29-offers-protection-against-severe-gastrointestinal-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/fda-approves-belumosudil-for-the-treatment-of-patients-with-cgvhd monthly 0.9 2025-07-21T10:50:00.000Z https://gvhdhub.com/medical-information/an-overview-of-developments-in-reduced-intensity-conditioning-and-gvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/gut-microbiota-restoration-after-autologous-fecal-microbiota-transfer-in-patients-with-aml monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-anti-il-2-antibody-jes-6-demonstrates-attenuation-of-gvhd-while-preserving-gvl monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-are-the-main-challenges-when-evaluating-novel-agents-for-gvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/are-you-planning-a-phase-ii-study-of-glasdegib-in-refractory-sclerotic-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/key-communications-on-gvhd-at-eha-2021 monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/gene-polymorphisms-in-the-cyclophosphamide-metabolism-pathway-correlate-with-complications-after-haplo-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-are-the-unique-challenges-to-cmv-prophylaxis-in-patients-with-acute-or-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/a-dose-ranging-study-of-gvhd-prophylaxis-with-ptb-in-patients-with-refractory-acute-leukemia monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/real-world-qol-survey-for-patients-with-acute-and-chronic-gvhd-post-allo-sct-in-5-european-countries monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/sting-pathways-and-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/combination-of-myeloablative-conditioning-with-regulatory-and-conventional-t-cell-immunotherapy-for-aml monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/a-phase-ii-trial-of-ptcy-versus-atg-for-gvhd-prophylaxis-after-ric-regimen-allo-hct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/investigational-new-drug-status-and-fast-track-designation-granted-by-fda-to-smart-101-a-progenitor-t-cell-product-for-aml-and-all monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/covid-19-vaccination-for-hematopoietic-stem-cell-transplant-patients monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/targeting-cd6-t-cells-as-a-promising-strategy-for-treating-acute-gvhd-an-interview-with-benedetta-rambaldi monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/impact-of-viral-infection-on-post-hsct-mixed-t-cell-chimerism-in-pediatric-patients-receiving-alemtuzumab-conditioning monthly 0.9 2024-07-17T11:08:00.000Z https://gvhdhub.com/medical-information/should-we-be-mindful-of-drug-interactions-between-alternative-medicines-and-gvhd-treatments monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-latest-updates-on-cgvhd-treatment monthly 0.9 2024-07-17T11:17:00.000Z https://gvhdhub.com/medical-information/how-can-patient-reported-qol-change-our-view-on-unmet-needs-in-gvhd monthly 0.9 2021-11-16T11:18:00.000Z https://gvhdhub.com/medical-information/is-dpp-4-inhibition-a-feasible-strategy-for-preventing-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/should-omidubicel-become-soc-for-umbilical-cord-blood-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/strategies-to-improve-hematopoietic-stem-cell-engraftment-and-reduce-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/why-is-it-important-to-assess-the-organ-specific-gvhd-responses-to-treatments monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-is-the-mechanism-of-action-of-the-glp-2-analog-teduglutide-for-gvhd-treatment monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/updated-results-from-reach2-ruxolitinib-for-steroid-refractory-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-can-cmv-infection-increase-the-risk-of-chronic-gvhd monthly 0.9 2024-07-17T11:08:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-using-a-stem-cell-source-as-prophylaxis-for-cgvhd monthly 0.9 2024-07-17T11:18:00.000Z https://gvhdhub.com/medical-information/reach2-study-what-is-the-risk-of-losing-response-to-ruxolitinib-over-time monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/do-we-see-differences-after-cord-blood-transplantation-between-european-and-japanese-patients monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/fda-grants-orphan-drug-designation-to-axatilimab-for-the-treatment-of-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/phase-ii-trial-of-arsenic-trioxide-for-chronic-gvhd-meets-its-primary-endpoint monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-can-we-use-microbial-derived-metabolites-to-prevent-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-effect-of-obesity-on-acute-gvhd-outcomes-following-allogeneic-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-is-the-impact-of-chronic-gvhd-on-first-late-effects-in-transplant-survivors monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/de-escalation-of-posttransplant-cyclophosphamide-in-preventing-acute-graft-versus-host-disease monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/nccn-covid-19-vaccination-recommendations-for-patients-with-hematologic-malignancies monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/phase-ii-heracles-trial-meets-its-primary-objective monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/when-would-you-favor-ptcy-over-csamtx-as-gvhd-prophylaxis-after-matched-sibling-donor-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/a-phase-iii-trial-of-omidubicel-versus-standard-umbilical-cord-blood-for-improved-stem-cell-engraftment monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-is-the-impact-of-conditioning-regimens-on-microbiota monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/outcomes-of-thiotepabusulfanudarabine-conditioning-in-patients-with-myelofibrosis-undergoing-allo-hct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/t-cell-costimulation-blockade-with-abatacept-for-acute-gvhd-results-of-the-aba2-trial-with-subanalysis-from-the-tct-2021-meeting monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/preliminary-data-from-novel-dli-strategies-show-a-lower-risk-of-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/fda-grants-fast-track-designation-for-neihulizumab-in-steroid-refractory-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/does-omidubicel-reduce-the-rate-of-gvhd-compared-to-standard-cord-blood-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/in-what-setting-is-abatacept-most-effective-as-gvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-should-we-manage-highly-morbid-forms-of-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-clinical-manifestations-and-pathophysiology-of-chronic-gvhd monthly 0.9 2025-10-01T16:07:00.000Z https://gvhdhub.com/medical-information/how-can-day-100-transcriptomics-help-to-predict-development-of-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/bmt-ctn-1202-biorepository-study-report-on-acute-gvhd-diagnosis-and-adjudication monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/fda-accepts-a-supplemental-new-drug-application-for-ruxolitinib-in-steroid-refractory-cgvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/can-we-prevent-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/gravitas-119-a-phase-i-trial-of-itacitinib-plus-calcineurin-inhibitor-based-regimens-for-gvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-is-new-in-haploidentical-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/new-insights-highlight-the-association-of-scfa-producing-bacteria-and-response-to-acute-gvhd-treatments monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/orca-t-an-engineered-treg-donor-product-as-an-agvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/preventative-treatment-for-gvhd-in-patients-requiring-haploidentical-peripheral-blood-stem-cell-transplant-preliminary-findings-from-the-phase-ii-anzhit-1-study monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-rockstar-study-kd025-213-what-patients-with-chronic-gvhd-benefit-most-from-belumosudil monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/is-the-microbiota-biotherapeutic-maat013-a-safe-and-effective-option-for-steroid-refractory-gi-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-is-new-for-treating-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-results-of-the-expanded-access-program-using-maat013-for-steroid-refractory-gi-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/rockstar-belumosudil-in-chronic-gvhd-an-update-from-ash-2020 monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/sodium-bicarbonate-gives-exhausted-tumor-killing-t-cells-a-lift-after-allogeneic-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/novel-drugs-for-treating-cgvhd-phase-i-results-of-axatilimab-for-heavily-pretreated-patients monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/novel-drugs-for-treating-cgvhd-preliminary-phase-iii-results-for-baricitinib monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/reach3-study-should-ruxolitinib-become-soc-for-steroid-dependent-or-refractory-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-does-stem-cell-source-impact-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/can-the-antigen-specific-cd8-t-cell-product-nexi-001-be-safely-and-effectively-applied-in-patients monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/positive-results-from-the-phase-iii-reach3-trial-of-ruxolitinib-for-patients-with-sr-cgvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/epigenetic-regulation-of-gvhd-pathophysiology monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/high-vs-low-dose-antithymocyte-globulin-for-pediatric-patients-with-leukemia-undergoing-allo-pbsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/constitutive-gp130-activity-improves-car-t-cell-expansion-cytotoxicity-and-anti-tumor-potential monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ash-2020-highlights-for-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-is-the-evidence-that-fecal-microbiota-transplantation-can-cure-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-plasma-short-chain-fatty-acids-are-predictors-of-response-to-gvhd-therapy monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-fails-to-provide-clinical-benefit-in-patients-with-covid-19-related-cytokine-storm monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/comparable-outcomes-for-gvhd-prophylaxis-with-ptcy-or-atg-in-patients-with-aml-transplanted-from-matched-sibling-donors monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/nm-003-receives-orphan-drug-designation-from-fda monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/naive-t-cell-depletion-in-allogeneic-hematopoietic-stem-cell-transplant-current-progress monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/is-the-treg-engineered-donor-product-orca-t-safe-and-effective-at-preventing-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/impact-of-lysosomal-acid-lipase-inhibition-in-controlling-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/targeting-the-icos-icosl-costimulatory-pathway-in-gastrointestinal-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/review-of-oral-and-gut-microbiome-signatures-in-allo-hsct-associated-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/role-of-the-type-2-cannabinoid-receptor-in-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/prolactin-as-a-biomarker-for-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-role-of-the-microbiome-in-the-pathogenesis-and-severity-of-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/restoration-of-gut-microbial-diversity-by-donor-fmt-could-resolve-gi-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/use-of-prebiotics-as-gvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/pomalidomide-in-chronic-gvhd-efficacy-and-safety monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-latest-advances-in-microbiome-interventions monthly 0.9 2024-07-17T11:15:00.000Z https://gvhdhub.com/medical-information/frontline-ruxolitinib-plus-methylprednisolone-for-acute-gvhd-treatment-following-haplo-sct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/a-novel-rxr-agonist-irx4204-reduces-gvhd-while-maintaining-gvl-effect monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-impact-of-carfilzomib-as-gvhd-prophylaxis-in-patients-transplanted-from-unrelated-donors monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/influence-of-rate-of-neutrophil-recovery-on-the-incidence-of-gvhd monthly 0.9 2025-10-01T16:07:00.000Z https://gvhdhub.com/medical-information/regenerative-medicine-advanced-therapy-and-orphan-drug-designation-given-to-orca-t monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-impact-of-jak-inhibitor-use-on-hsct-outcome-in-patients-with-mpn monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/kd025-for-chronic-gvhd-an-update monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/phase-ii-results-of-natalizumab-plus-steroids-for-gastrointestinal-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/fda-rejects-remestemcel-l-for-the-treatment-of-steroid-refractory-agvhd-pending-further-study monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/a-matter-of-size-telomere-length-predicts-survival-before-allo-sct-in-patients-with-mds monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/new-drug-application-submitted-for-belumosudil-to-fda monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/non-hla-characteristics-donor-age-and-kinship-affect-haplo-sct-outcomes monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/establishing-the-optimal-co-receptor-signaling-domain-for-chimeric-antigen-receptor-treg-cell-therapy monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-using-posttransplant-cyclophosphamide-and-antithymocyte-globulin-after-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/in-vitro-and-in-vivo-studies-in-mouse-models-elucidate-the-protective-role-of-bile-acids-during-intestinal-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/use-of-ruxolitinib-in-patients-with-severe-covid-19 monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-should-antibiotics-be-administered-in-transplant-patients-to-reduce-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/new-working-definition-of-ruxolitinib-refractory-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/a-comparison-of-gvhd-characteristics-in-recipients-of-haploidentical-vs-matched-unrelated-donor-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/sting-regulates-gvhd-through-cd8-and-cd4-t-cell-subsets monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/practice-changing-abstracts-at-asco-and-eha-2020 monthly 0.9 2022-09-02T08:55:00.000Z https://gvhdhub.com/medical-information/can-the-combination-of-hdac-inhibitor-panobinostat-plus-tacrolimus-and-sirolimus-reduce-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/why-is-regulatory-t-cell-reconstitution-important-to-prevent-gvhd-in-allo-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/unusual-manifestations-of-acute-gvhd monthly 0.9 2024-06-25T15:39:00.000Z https://gvhdhub.com/medical-information/the-microbiome-and-its-effects-on-the-immune-system monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/why-can-ctla4ig-primed-sequential-dli-improve-chronic-gvhd-and-rfs-after-allo-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-are-the-optimal-regimens-to-control-gvhd-after-haplo-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/do-pre-transplant-depression-and-anxiety-impact-on-the-development-of-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-are-the-latest-advances-in-microbiota-bioproducts monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/sildenafil-treatment-to-reduce-endothelial-damage-in-agvhd-and-sr-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/uhcg-plus-egf-granted-orphan-drug-designation-for-the-treatment-of-acute-graft-versus-host-disease monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/antithymocyte-globulin-decreases-acute-graft-versus-host-disease-following-hla-matched-sibling-donor-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/remestemcel-l-receives-backing-from-the-odac-for-the-treatment-of-children-with-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/alwpebmt-analysis-orflamsa-based-ric-vs-mic-in-young-patients-with-rr-aml monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/posttransplant-cyclophosphamide-for-gvhd-prophylaxis-after-allogeneic-hematopoietic-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/comparison-of-ptcy-with-antithymocyte-globulin-in-patients-with-aml-in-the-first-cr-undergoing-allo-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/positive-interim-results-of-the-equate-studyitolizumab-for-acute-graft-versus-host-disease monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/outcomes-of-two-or-more-hla-loci-mismatched-unrelated-donor-allo-hct-an-acute-leukemia-working-party-study monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-with-ptcy-allows-for-rapid-hematopoietic-reconstitution-and-improved-survival-in-transplanted-patients-with-severe-aplastic-anemia monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/phase-i-follow-up-results-for-cyp-001-a-mesenchymal-stem-cell-product-for-steroid-refractory-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/donor-macrophages-promote-human-acute-gvhd-in-allogeneic-bmt monthly 0.9 2025-10-01T16:06:00.000Z https://gvhdhub.com/medical-information/submission-of-biologics-license-application-to-fda-for-inolimomab-for-treatment-of-steroid-refractory-acute-gvhd-in-adult-patients monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/steroid-refractory-gvhd-long-term-outcomes-and-risk-factors monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-shows-improved-overall-response-rate-for-patients-with-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/is-arsenic-trioxide-effective-in-treating-agvhd-results-from-an-in-vitro-study monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/can-ruxolitinib-be-safely-combined-with-regulatory-t-cells-to-enhance-efficacy-in-treating-cgvhd monthly 0.9 2025-10-01T16:04:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-considerations-for-allo-hsct-from-mismatched-unrelated-donors monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/a-retrospective-analysis-of-allogeneic-stem-cell-transplantation-for-peripheral-t-cell-lymphoma monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/eha-2020-or-phase-iii-gravitas-301-trial-results-on-itacitinib-plus-corticosteroids-for-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/comparison-of-reduced-intensity-conditioning-regimens-for-allo-hsct-in-patients-with-all monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-protective-role-of-short-chain-fatty-acids-from-the-development-of-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-role-of-the-nlrp3-inflammasome-in-hematological-pathologies monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-can-we-use-the-microbiome-to-improve-cancer-immunotherapy-and-alleviate-side-effect-such-as-graft-versus-host-disease monthly 0.9 2020-08-26T13:05:00.000Z https://gvhdhub.com/medical-information/ixazomib-for-advanced-chronic-gvhd-results-of-a-phase-ii-trial monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/two-different-treatment-approaches-in-combination-with-ecp-for-the-management-of-steroid-refractory-agvhd-etanercept-and-ruxolitinib monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/reach2-what-patients-with-steroid-refractory-acute-gvhd-respond-best-to-ruxolitinib monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/subgroup-analysis-of-ruxolitinib-in-patients-with-steroid-refractory-acute-gvhd-update-from-eha-2020 monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-factors-impact-response-to-mesenchymal-stromal-cells-in-patients-with-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/alpha-study-first-in-human-data-of-allo-501-and-allo-647-in-rr-large-b-cell-or-follicular-lymphoma monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-use-of-ptcy-as-gvhd-prophylaxis-in-patients-treated-with-checkpoint-inhibitors-prior-to-allo-hct-improves-outcomes monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-is-the-best-donor-or-graft-source-for-patients-lacking-hla-matched-donors monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/treatment-of-sr-gvhd-and-subsequent-trial-updates-at-eha-2020 monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/phase-i-results-of-the-selective-jak1-inhibitor-itacitinib-in-patients-with-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/an-overview-of-ebmt-recommendations-on-prophylaxis-and-treatment-of-acute-and-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/checkpoint-inhibition-before-haploidentical-transplantation-with-posttransplant-cyclophosphamide-as-gvhd-prophylaxis-in-patients-with-classic-hodgkin-lymphoma monthly 0.9 2025-10-01T16:03:00.000Z https://gvhdhub.com/medical-information/beclomethasone-and-budesonide-to-treat-patients-with-upper-gastrointestinal-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/post-transplant-cyclophosphamide-and-ruxolitinib-as-gvhd-prophylactic-regimen-in-patients-with-primary-or-secondary-myelofibrosis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/comparison-of-ruxolitinib-with-other-therapies-for-steroid-refractory-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/positive-topline-results-of-belumosudil-kd025-in-patients-with-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/gvhd-staging-grading-pathophysiology-and-novel-targets-ebmt-webinar-summary monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/safety-of-trial-participants-is-fda-s-top-priority-in-ongoing-clinical-trials-during-the-covid-19-outbreak monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/phase-ii-study-of-maraviroc-as-agvhd-prophylaxis-in-children-and-young-adults monthly 0.9 2025-10-01T15:57:00.000Z https://gvhdhub.com/medical-information/prognostic-factors-for-the-response-to-basiliximab-treatment-and-the-long-term-clinical-outcomes-of-patients-with-sr-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-effect-of-choline-rich-diet-on-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/impact-of-cd34-cell-dose-on-the-outcome-of-patients-with-acute-myeloid-leukemia-in-complete-remission-after-t-cell-replete-haploidentical-hsct-using-peripheral-blood-stem-cells monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/management-of-patients-with-steroid-refractory-acute-graft-versus-host-disease-treatment-options-and-unmet-clinical-need monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/covid-heme-forum-supports-hematologists-during-covid-19-pandemic monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ebmt-alwp-recommendations-for-transplantation-in-patients-with-flt3-itd-aml monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/the-predictive-value-of-specific-biomarkers-in-acute-and-chronic-gvhd-after-allo-hsct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/management-of-covid-19-outbreak-on-transplant-wards monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/bcl2-as-a-new-target-for-the-treatment-of-sr-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/summary-of-tct-2020-highlights-gvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/treosulfanfludarabinethiotepa-conditioning-treatment-before-allogeneic-hematopoietic-stem-cell-transplantation-for-children-with-hematological-malignancies monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/mortality-risk-stratification-in-patients-with-agvhd-using-allo-grrr-oh-score monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-late-effects-of-allogenic-hematopoietic-cell-therapy-in-adolescent-and-young-adults-with-acute-myeloid-leukemia monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/caring-for-patients-with-hematological-malignancies-during-the-covid-19-pandemic-recommendations-from-iach-eha-and-ebmt monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/using-microbiota-to-predict-post-transplant-mortality monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-novel-targets-for-the-treatment-of-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/expert-opinion-from-our-chair-mohamad-mohty-on-covid-19-and-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/fda-grants-alpn-101-an-orphan-drug-designation-for-the-prevention-and-treatment-of-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/fda-grants-priority-review-of-remestemcel-l-for-certain-children-with-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/post-transplant-cyclophosphamide-for-the-management-of-gvhd-in-patients-receiving-immune-checkpoint-inhibitors-for-amlmds monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/covid-19-and-ebmt-recommendations-for-patients-with-hematological-malignancies monthly 0.9 2021-03-17T14:33:00.000Z https://gvhdhub.com/medical-information/the-correlation-between-cd34-cell-dose-and-dfs-in-matched-related-donor-pbsc-allo-sct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/prospective-study-investigating-a-mesenchymal-stem-cells-infusion-remestemcel-l-in-pediatric-patients-with-steroid-refractory-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/results-of-the-ablepbmtc-1202-studies-demonstrate-biological-differences-between-cgvhd-and-late-agvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/f-652-for-agvhd-of-the-lower-gi-tract monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/could-dual-targeting-of-tnfrsf25-and-cd25-minimize-gastrointestinal-graft-versus-host-disease monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ccr7-as-a-potential-therapeutic-target-for-gvhd-results-from-preclinical-models monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-role-of-microglia-in-cns-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/effects-of-defibrotide-preventive-treatment-on-acute-graft-versus-host-disease-after-allogeneic-hematopoietic-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/refined-national-institutes-of-health-response-algorithm-for-joint-and-fascia-associated-chronic-graft-versus-host-disease monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/non-myeloablative-haploidentical-or-unrelated-cord-blood-hematopoietic-transplant-for-hodgkin-and-non-hodgkin-lymphoma monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/updated-consensus-of-the-ebmt-or-prophylaxis-and-management-of-post-transplant-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/anti-thymocyte-globulin-pre-treatment-plus-standard-gvhd-prophylaxis-beneficial-for-patients-undergoing-unrelated-donor-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/editorial-theme-or-novel-therapies-for-the-treatment-of-gvhd monthly 0.9 2025-10-01T15:39:00.000Z https://gvhdhub.com/medical-information/at-home-allo-hsct-program-or-hospital-clinic-of-barcelona monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/decitabine-containing-conditioning-regimen-for-allo-hsct-decreases-incidence-of-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/impact-of-atg-on-post-allo-hsct-outcomes-by-pre-transplant-mrd-status monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/bmt-ctn-1501-sirolimus-versus-prednisone-for-initial-treatment-of-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/lactose-driven-enterococcus-expansion-linked-to-unfavorable-prognosis-in-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/vedolizumab-treatment-for-the-prevention-of-acute-gvhd-following-allogeneic-hematopoietic-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-comparison-of-reduced-intensity-stem-cell-transplantation-conditioning-regimens-in-patients-with-high-risk-aml monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-phase-iii-gravitas-301-study-did-not-meet-its-primary-endpoint-of-improving-overall-response-rate-orr monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/impact-of-donor-clonal-hematopoiesis-in-older-matched-related-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-s-new-in-microbiota-research-on-the-outcomes-after-allogeneic-hematopoietic-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/molecular-profiling-at-diagnosis-for-risk-stratification-of-patients-with-aml-undergoing-allogeneic-transplant-in-first-remission monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/efficacy-of-tocilizumab-add-on-treatment-to-prevent-acute-gvhd-after-hla-matched-allogeneic-stem-cell-transplantation-results-from-a-phase-iii-study monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/pre-transplant-serum-levels-of-claudin-3-as-a-predictive-biomarker-for-intestinal-gvhd-and-non-relapse-mortality-risk-after-allogeneic-transplantation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/investigating-the-feasibility-of-induced-pluripotent-stem-cell-ipsc-banking-and-transplantation-in-allogeneic-settings monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/practice-changing-abstracts-for-gvhd-from-ash-2019 monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-is-the-best-way-to-measure-response-to-gvhd-treatment monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/is-sustained-treatment-with-kd025-required-for-cgvhd-control monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-to-select-the-optimal-gvhd-prophylaxis-regimen monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-do-you-select-the-optimal-donor-for-transplant monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-krp203-plus-post-transplant-cyclophosphamide monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/is-the-composition-of-gut-fungal-microbiota-a-predictor-of-mortality-after-allo-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/novel-prophylactic-therapies-available-before-and-after-transplantation-to-reduce-the-risk-of-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/what-is-new-in-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/how-can-we-maintain-a-high-diversity-microbiome-after-allo-transplant monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/should-patients-with-high-pre-transplant-serum-claudin-3-be-treated-differently monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/abatacept-granted-breakthrough-therapy-designation-for-the-prevention-of-acute-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/monthly-theme-or-predictive-factors-for-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/non-myeloablative-conditioning-prior-to-allogeneic-stem-cell-transplantation-in-patients-with-acute-myelogenous-leukemia monthly 0.9 2025-10-01T15:40:00.000Z https://gvhdhub.com/medical-information/the-role-of-butyrogenic-bacteria-after-the-onset-of-acute-graft-versus-host-disease-agvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/treosulfan-or-busulfan-plus-fludarabine-as-conditioning-treatment-before-allogeneic-hemopoietic-stem-cell-transplantation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/key-publications-selected-by-the-gvhd-hub-steering-committee monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/impact-of-donor-type-on-outcomes-of-allogeneic-transplant monthly 0.9 2025-10-01T15:40:00.000Z https://gvhdhub.com/medical-information/effect-of-conditioning-regimen-intensity-after-haploidentical-transplantation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/post-transplant-outcomes-of-patients-with-therapy-related-aml-following-treatment-for-prior-lymphoid-malignancy monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/hla-dpb1-mismatch-models-after-unrelated-donor-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/mrd-negativity-after-tandem-autologous-allogeneic-hsct-with-bortezomib-maintenance monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-in-mismatched-unrelated-allogeneic-stem-cell-transplant-a-comparison-of-post-transplant-cyclophosphamide-and-anti-thymocyte-globulin monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/monthly-theme-or-gvhd-prophylaxis monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/cannabidiol-cbd-receives-notice-of-allowance-for-eu-patent-for-the-prevention-and-treatment-of-graft-versus-host-disease-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/nlrp6-aggravates-graft-versus-host-disease-gvhd-regardless-of-gut-microbial-composition monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/haploidentical-transplantation-versus-unrelated-donor-hematopoietic-stem-cell-transplantation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/fda-grants-the-investigational-new-drug-designation-for-pbcar20a-a-car-t-cell-therapy monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/educational-theme-impact-of-the-stem-cell-source-on-gvhd monthly 0.9 2025-10-01T15:41:00.000Z https://gvhdhub.com/medical-information/increased-incidence-of-intestinal-gvhd-with-broad-spectrum-antibiotic-use monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/positive-results-for-cannabidiol-cbd-for-the-prevention-of-acute-graft-versus-host-disease-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ileostomy-for-steroid-resistant-acute-graft-versus-host-disease-of-the-gastrointestinal-tract monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/adipose-tissue-derived-mesenchymal-stem-cells-protect-against-bone-marrow-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/prophylaxis-of-graft-versus-host-disease-gvhd-with-sirolimus-plus-cyclosporine-and-mycophenolate-mofetil monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/educational-theme-or-the-role-of-the-microbiome-in-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/impact-of-antithymocyte-globulin-and-total-body-irradiation-on-outcomes-of-allogeneic-hematopoietic-cell-transplantation-in-patients-with-acute-myeloid-leukemia monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/haploidentical-vs-haplo-cord-transplant-in-adults-receiving-fludarabine-and-melphalan-conditioning monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/coping-and-psychological-factors-associated-with-quality-of-life-in-cgvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/impact-of-mesenchymal-stem-cells-in-the-hematopoietic-stem-cell-transplantation-on-prevention-and-treatment-of-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/july-2019-or-conditioning-regimens-for-stem-cell-transplantation-in-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/eha-2019-orthe-role-of-inkt-cells-in-car-immunotherapy-and-acute-graft-versus-host-disease-prophylaxis monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/eha-2019-or-the-role-of-intestinal-microbiota-in-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/effect-of-alemtuzumab-on-gvhd-prevention-viral-reactivation-and-t-cell-dynamics monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/eha-2019-or-should-we-use-ptcy-or-atg-as-gvhd-prophylaxis-in-haploidentical-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/eha-2019-or-what-are-the-current-treatment-recommendations-for-acute-gvhd-and-the-promotion-of-the-gvl-effect monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/eha-2019-or-clinical-practice-in-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/eha-2019-or-how-can-we-better-utilize-fmt-in-patients-undergoing-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/asco-2019-or-results-of-a-phase-ii-study-post-transplant-cyclophosphamide-in-matched-and-haploidentical-transplant-recipients-receiving-myeloablative-timed-sequential-busulfan-conditioning-regimen monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-gvhd-summit-2019-or-acute-gvhd-diagnosis monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/fda-agrees-to-a-rolling-review-towards-the-bla-for-remestemcel-l-in-the-treatment-of-agvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-gvhd-summit-2019-or-treatment-of-acute-gvhd-based-on-the-ebmteln-working-group-recommendations monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-gvhd-summit-2019-or-prophylaxis-of-gvhd-ebmteln-working-group-recommendations monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-approved-by-the-fda-for-steroid-refractory-acute-gvhd monthly 0.9 2025-07-21T10:49:00.000Z https://gvhdhub.com/medical-information/post-transplant-cyclophosphamide-use-in-matched-hla-donors monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/highlights-from-the-1st-ebmt-gvhd-summit-2019 monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/pathogenicity-and-alloresponse-of-t-cells-confined-by-thioredoxin-1 monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/myd88-signaling-in-donor-t-cells-accelerates-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/chronic-gvhd-management-and-future-perspectives monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/impact-of-cyclosporine-a-concentration-on-agvhd-incidence-after-haplo-hct monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/clinical-features-of-cgvhd-following-cord-blood-infused-haploidentical-transplantation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/combination-atg-and-ptcy-results-in-low-rates-of-cgvhd-and-agvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ruxolitinib-treatment-for-patients-with-steroid-refractory-gvhd-following-hematopoietic-stem-cell-transplantation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2019-or-incorporation-of-pt-cy-as-standard-of-care-prophylaxis-in-patients-with-an-increased-risk-of-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2019-or-results-from-the-pbmtc-1202able-study-biological-differences-between-pediatric-late-agvhd-and-cgvhd-by-biomarker-analysis monthly 0.9 2025-10-01T15:42:00.000Z https://gvhdhub.com/medical-information/ebmt-2019-or-treatment-of-steroid-resistant-gastrointestinal-graft-versus-host-disease-using-a1-antitrypsin monthly 0.9 2025-10-01T15:43:00.000Z https://gvhdhub.com/medical-information/embt-2019-or-immune-modifying-micro-particles-in-an-acute-graft-versus-host-disease-model monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2019-or-graft-versus-host-disease-prophylaxis-with-reduced-intensity-conditioning-regimen-combined-with-anti-thymocyte-globulin-and-post-transplantation-cyclophosphamide-for-aml monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2019-or-begelomab-an-anti-cd26-monoclonal-antibody-for-the-treatment-of-steroid-refractory-gvhd monthly 0.9 2025-10-01T15:44:00.000Z https://gvhdhub.com/medical-information/ebmt-2019-or-endothelial-protection-in-steroid-refractory-gvhd monthly 0.9 2025-10-01T15:46:00.000Z https://gvhdhub.com/medical-information/ebmt-2019-or-endothelial-activation-and-stress-index-easix-to-predict-outcome-after-allogeneic-hematopoietic-cell-transplantation-allo-hct monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2019-or-influence-of-inflammatory-bowel-disease-on-the-outcome-of-allogeneic-stem-cell-transplantation-a-matched-pair-analysis monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/marcel-van-den-brink-or-ebmt-2019-or-microbiome-changes-in-allogeneic-hematopoietic-sct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/arnon-nagler-or-ebmt-2019-or-haploidentical-hematopoietic-transplantation-current-status-and-future-perspectives monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/peter-bader-or-ebmt-2019-or-how-to-best-improve-long-term-outcomes-of-patients-with-steroid-refractory-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/kirk-schultz-or-ebmt-2019-or-biological-differences-found-by-the-pbmtc-1202able-study monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ali-bazarbachi-or-ebmt-2019-or-maintenance-treatment-after-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/madan-jagasia-or-ebmt-2019-or-six-month-follow-up-results-from-the-phase-ii-reach1-trial monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/betty-hamilton-or-ebmt-2019-or-what-are-the-current-treatment-options-for-genital-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/florent-malard-or-ebmt-2019-or-overview-of-the-phase-ii-heracles-study monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/robert-zeiser-or-ebmt-2019-or-insights-into-gvhd-pathophysiology-and-strategies-to-enhance-gvl-effects monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/bipin-savani-or-ebmt-2019-or-an-update-on-recent-advances-in-supportive-therapy-for-cgvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/takanori-teshima-or-ebmt-2019-or-treatment-options-for-patients-with-steroid-refractory-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/mohamad-mohty-or-ebmt-2019-or-a-message-from-our-chair monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/jean-el-cheikh-or-ebmt-2019-or-conditioning-regimens-in-patients-undergoing-stem-cell-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/zinaida-peric-or-ebmt-2019-or-retrospective-cohort-analysis-on-the-impact-of-ibd-after-allo-sct monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/attilio-olivieri-or-ebmt-2019-or-endothelial-damage-in-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/the-effect-of-kirhla-incompatibilities-on-patient-outcomes-in-the-setting-of-haploidentical-hematopoietic-stem-cell-transplant-with-post-transplant-cyclophosphamide monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/gut-microbiota-dynamics-in-relation-to-the-development-of-agvhd-in-pediatric-patients-following-allogeneic-hematopoietic-cell-transplantation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/results-from-the-phase-ii-bmt-ctn-1203-study-comparison-of-three-reduced-intensity-conditioning-regimens-to-prevent-graft-versus-host-disease-gvhd-with-hematopoietic-cell-transplantation monthly 0.9 2025-10-01T15:46:00.000Z https://gvhdhub.com/medical-information/tct-2019-or-pharmacodynamics-and-updated-data-from-the-phase-iia-kd025-208-trial monthly 0.9 2021-05-20T14:23:00.000Z https://gvhdhub.com/medical-information/tct-meeting-2019-or-primary-results-of-the-bmt-ctn-1501-trial-sirolimus-versus-prednisone-as-an-initial-steroid-free-treatment-for-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/tct-meeting-2019-or-a-report-from-the-bmt-ctn-1202-biorepository-trial-acute-graft-versus-host-disease-diagnosis-and-adjudication monthly 0.9 2021-02-25T11:34:00.000Z https://gvhdhub.com/medical-information/tct-meeting-2019-or-results-of-the-phase-ii-aba2-trial-abatacept-for-acute-gvhd-prophylaxis-in-unrelated-donor-transplantation monthly 0.9 2025-10-01T15:47:00.000Z https://gvhdhub.com/medical-information/tct-meeting-2019-or-results-from-the-reach1-trial-ruxolitinib-plus-corticosteroids-for-the-treatment-of-steroid-refractory-acute-graft-versus-host-disease monthly 0.9 2025-10-01T15:48:00.000Z https://gvhdhub.com/medical-information/tct-meeting-2019-or-azithromycin-for-the-management-of-moderate-to-severe-chronic-graft-versus-host-disease monthly 0.9 2025-10-01T15:49:00.000Z https://gvhdhub.com/medical-information/tct-meeting-2019-or-salivary-zymogen-granule-protein-16b-is-a-potential-salivary-biomarker-for-oral-chronic-graft-versus-host-disease monthly 0.9 2025-10-01T15:50:00.000Z https://gvhdhub.com/medical-information/tct-meeting-2019-or-gvhd-biomarker-algorithms-for-predicting-lethal-graft-versus-host-disease monthly 0.9 2025-10-01T15:51:00.000Z https://gvhdhub.com/medical-information/tct-meeting-2019-or-primary-data-from-a-phase-ii-trial-of-ixazomib-for-the-treatment-of-refractory-chronic-graft-versus-host-disease monthly 0.9 2025-10-01T15:53:00.000Z https://gvhdhub.com/medical-information/outpatient-surveillance-blood-cultures-in-patients-with-acute-graft-versus-host-disease-receiving-high-dose-steroids monthly 0.9 2025-10-01T15:55:00.000Z https://gvhdhub.com/medical-information/elevated-intestinal-epithelial-tight-junction-permeability-leads-to-systemic-graft-versus-host-disease-propagation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/the-prognostic-value-of-increased-b7-superfamily-proteins-in-acute-graft-versus-host-disease monthly 0.9 2025-10-01T15:56:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-practice-changing-abstracts-in-graft-versus-host-disease monthly 0.9 2025-10-01T15:56:00.000Z https://gvhdhub.com/medical-information/chronic-graft-versus-host-disease-newer-treatment-strategies monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/mycophenolate-mofetil-prophylaxis-and-treatment-in-pediatric-patients-with-graft-versus-host-disease monthly 0.9 2025-10-01T15:57:00.000Z https://gvhdhub.com/medical-information/intra-arterial-steroid-administration-in-patients-with-steroid-refractory-acute-gastrointestinal-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/cibmtrebmt-expert-review-of-ocular-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/acute-graft-versus-host-disease-newer-treatment-strategies monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/the-predictive-value-of-hy-antibodies-for-chronic-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/response-to-msc-treatment-at-one-week-predicts-probability-of-survival-in-patients-with-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-low-dose-il-2-therapy-increases-cd56bright-nk-cell-receptor-expression-in-patients-with-chronic-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-prediction-of-severe-chronic-graft-versus-host-disease-by-host-derived-cxcr3-ligand-genes monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-msc-ffm-for-the-treatment-of-pediatric-and-adult-patients-with-steroid-refractory-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-vedolizumab-plus-standard-of-care-to-prevent-graft-versus-host-disease-a-phase-ib-study monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-the-role-of-metabolomics-profiling-in-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-early-prediction-of-moderate-severe-chronic-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-phase-i-study-of-hcgegf-adjunct-therapy-in-high-risk-and-steroid-refractory-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/peter-bader-or-ash-2018-or-msc-ffm-for-patients-with-refractory-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/florent-malard-or-ash-2018-or-extracorporeal-photopheresis-for-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/shernan-holtan-or-ash-2018-or-human-chorionic-gonadotropin-and-epidermal-growth-factor-in-acute-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-prediction-of-acute-graft-versus-host-disease-with-a-machine-learning-algorithm monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/amit-kalra-or-ash-2018-or-early-prediction-of-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/yi-bin-chen-or-ash-2018-or-vedolizumab-plus-standard-of-care-for-gvhd-prophylaxis monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-validation-study-of-the-minnesota-acute-gvhd-risk-score monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/james-ferrara-or-ash-2018-or-how-biology-drives-acute-gvhd-biomarkers monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/yasuyuki-arai-or-ash-2018-or-the-role-of-machine-learning-algorithms-in-gvhd-risk-prediction monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-pharmacodynamics-and-updated-data-from-the-phase-iia-kd025-208-trial monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/kate-a-markey-or-ash-2018-or-pre-transplant-and-peri-d100-gastrointestinal-dysbiosis-in-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/kristina-maas-bauer-or-ash-2018-or-the-role-of-invariant-natural-killer-t-cell-subsets-in-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/robert-zeiser-or-ash-2018-or-novel-therapeutic-strategies-for-the-treatment-of-steroid-refractory-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/madan-jagasia-or-ash-2018-or-kd025-for-patients-with-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ash-2018-or-ruxolitinib-plus-corticosteroids-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-the-reach1-trial monthly 0.9 2025-10-01T15:58:00.000Z https://gvhdhub.com/medical-information/betty-hamilton-or-ash-2018-or-novel-prophylactic-strategies-for-the-prevention-of-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/mohamad-mohty-or-ash-2018-or-highlights-of-gvhd-at-ash-2018 monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/madan-jagasia-or-ash-2018-or-results-from-the-phase-ii-reach1-trial-in-patients-with-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/etanercept-for-the-treatment-of-pediatric-patients-with-steroid-refractory-graft-versus-host-disease monthly 0.9 2025-10-01T15:57:00.000Z https://gvhdhub.com/medical-information/low-dose-anti-thymocyte-globulin-plus-low-dose-posttransplant-cyclophosphamide-as-graft-versus-host-disease-prophylaxis-in-haploidentical-transplantation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/anti-cd3cd7-immunotoxins-for-the-treatment-of-steroid-refractory-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/extracorporeal-photopheresis-for-the-treatment-of-acute-and-chronic-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/vedolizumab-for-the-treatment-of-steroid-resistant-severe-intestinal-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/predictive-plasma-based-protein-biomarkers-for-patients-with-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/brentuximab-vedotin-for-steroid-refractory-chronic-graft-versus-host-disease-a-phase-i-study monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/kd025-granted-breakthrough-therapy-designation-for-the-treatment-of-patients-with-chronic-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/phase-ii-study-on-maraviroc-for-the-prevention-of-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/iach-2018-or-management-of-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/graft-versus-host-disease-and-chromosome-y-encoded-antigens-in-sex-mismatched-stem-cell-transplant monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/bcl6-inhibition-in-murine-chronic-graft-versus-host-disease-model monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/the-role-of-cd56bright-natural-killer-cells-in-extracorporeal-photopheresis monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/iach-2018-or-calcineurin-and-mtor-inhibitor-free-graft-versus-host-disease-prevention monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/polymyositis-related-chronic-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/could-a-machine-learning-algorithm-help-to-better-stratify-chronic-graft-versus-host-disease-survival-and-phenotypes monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/the-overall-prevalence-of-chronic-graft-versus-host-disease-related-alopecia-and-nail-dystrophy monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/the-diagnostic-yield-of-endoscopy-combined-with-tissue-sampling-in-gastrointestinal-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/analysis-of-ruxolitinib-as-salvage-therapy-in-patients-with-chronic-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/checkpoint-inhibitors-administered-before-and-after-allo-hsct-may-increase-the-risk-of-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/pericarditis-in-chronic-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/calcineurin-inhibitor-based-methotrexate-and-mycophenolate-mofetil-regimens-as-graft-versus-host-disease-prophylaxis-after-reduced-intensity-conditioning-allogeneic-transplantation monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/graft-versus-host-disease-of-the-tongue-and-oral-cavity monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/insulin-therapy-with-a-standardized-decision-support-system-for-acute-graft-versus-host-disease-patients-with-steroid-induced-hyperglycemia monthly 0.9 2025-10-01T15:59:00.000Z https://gvhdhub.com/medical-information/analysis-of-additional-treatment-strategies-for-refractory-gastrointestinal-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/a-meta-analysis-of-mesenchymal-stromal-cells-for-the-prophylaxis-of-chronic-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/comparison-of-the-original-and-the-revised-nih-chronic-graft-versus-host-disease-scoring-criteria monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/interleukin-22-levels-in-pediatric-patients-with-gastrointestinal-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/the-prognostic-impact-of-upper-gastrointestinal-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/survey-on-manufacturing-mscs-for-the-treatment-of-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/mycophenolate-mofetil-plus-tacrolimus-as-acute-gvhd-prophylaxis-in-pediatric-patients monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/tacrolimus-and-thymoglobulin-as-gvhd-prophylaxis-in-patients-undergoing-related-donor-allogeneic-hct monthly 0.9 2025-10-01T15:56:00.000Z https://gvhdhub.com/medical-information/the-role-of-clostridium-difficile-infection-in-gastrointestinal-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/study-finds-no-significant-associations-between-donor-bmi-and-gvhd-after-hct monthly 0.9 2025-10-01T16:00:00.000Z https://gvhdhub.com/medical-information/a-review-of-cns-involvement-in-gvhd-from-case-reports-and-published-literature monthly 0.9 2025-10-01T16:01:00.000Z https://gvhdhub.com/medical-information/villous-atrophy-in-the-terminal-ileum-can-predict-the-severity-of-graft-versus-host-disease-after-allo-hsct monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ric-and-dual-t-lymphocyte-suppression-with-anti-thymocyte-globulin-and-post-transplant-cyclophosphamide-as-gvhd-prophylaxis-in-haplo-sct monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/gastrointestinal-graft-versus-host-disease-increases-the-risk-of-post-engraftment-bloodstream-infections monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/lower-pre-transplant-serum-citrulline-level-as-predictive-marker-for-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/the-impact-of-antibiotics-on-acute-graft-versus-host-disease-development monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/position-statement-on-standardized-terminology-and-guidance-for-graft-versus-host-disease-assessment-by-gvhd-experts-from-the-ebmt-the-nih-and-the-cibmtr monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/prednisonesirolimus-vs-prednisonesirolimuscalcineurin-inhibitor-for-the-treatment-of-chronic-graft-versus-host-disease monthly 0.9 2025-10-01T15:41:00.000Z https://gvhdhub.com/medical-information/extracorporeal-photopheresis-in-steroid-refractory-or-steroid-dependent-acute-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/abatacept-in-steroid-refractory-chronic-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/antonio-galleu-or-eha-2018-or-the-role-of-mesenchymal-stromal-cells-in-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/eha-2018-or-interim-phase-ii-results-of-azacitidine-for-acute-gvhd-prophylaxis monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/eha-2018-or-jak-inhibition-in-steroidrefractory-gvhd monthly 0.9 2025-10-01T16:01:00.000Z https://gvhdhub.com/medical-information/mette-hazenberg-or-eha-2018-or-fmt-as-therapy-for-steroid-refractory-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/roni-shouval-or-eha-2018-or-fecal-microbiota-transplantation-for-the-treatment-of-agvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/eha-2018-or-updates-from-the-kd025-208-study monthly 0.9 2025-10-01T16:02:00.000Z https://gvhdhub.com/medical-information/attilio-olivieri-or-eha-2018-or-extracorporeal-photopheresis-in-acute-and-chronic-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/mohamad-mohty-or-eha-2018-or-launch-of-the-gvhd-hub monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/egvhd-app-for-gvhd-assessment monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/gvhd-prophylaxis-which-one-is-better-comparison-of-single-agent-post-transplantation-cyclophosphamide-and-calcineurin-inhibitors monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/prof-robert-zeiser-or-ebmt-2018-or-the-role-of-myeloid-recipient-derived-cells-during-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-vedolizumab-for-the-treatment-of-steroid-resistant-severe-intestinal-agvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-chronic-and-late-acute-graft-versus-host-disease-defined-by-the-2005-nih-criteria-a-prospective-validation-of-a-japanese-cohort monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-can-microbiome-markers-predict-acute-gvhd-after-allo-hsct monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-a-phase-ii-study-to-evaluate-the-safety-tolerability-and-activity-of-kd025-in-subjects-with-chronic-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/prof-bipin-n-savani-or-ebmt-2018-or-supportive-care-after-bmt monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-the-minnesota-refined-acute-gvhd-score-is-useful-to-identify-high-risk-patients-after-haploidentical-transplantation-with-post-transplant-cyclophosphamide monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/dr-frederic-baron-or-ebmt-2018-or-the-role-of-azacitidine-in-gvhd-prevention monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-mre-for-the-diagnosis-and-staging-of-intestinal-agvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-elafin-is-a-potential-biomarker-for-acute-skin-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/prof-h-joachim-deeg-or-ebmt-2018-or-treatment-of-steroid-refractory-gvhd-with-alpha-1-antitrypsin monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-a-new-endpoint-that-accurately-recognizes-the-long-term-outcomes-of-allo-hct-in-refractory-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/prof-attilio-olivieri-or-ebmt-2018-or-what-current-therapies-are-available-for-refractory-cgvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-reducing-gvhd-with-fms-like-receptor-tyrosine-kinase-3-ligand-treatment-of-bone-marrow-donors monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/ebmt-2018-or-ccr5-and-cxcr3-blockade-attenuation-of-murine-agvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/tocilizumab-for-gvhd-prophylaxis-a-phase-ii-study monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/crp-levels-as-a-predictor-of-allogeneic-transplant-outcomes monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/less-invasive-diagnosis-of-gastrointestinal-graft-versus-host-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/bmt-tandem-meetings-or-study-design-of-the-reach-3-trial-using-ruxolitinib-in-steroid-refractory-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/post-transplant-cyclophosphamide-as-sole-gvhd-prophylaxis-a-phase-ii-study monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/bmt-tandem-meetings-or-rituximab-first-line-therapy-for-chronic-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/bmt-tandem-meetings-or-mycophenolate-mofetil-comparison-to-methotrexate-for-gvhd-prophylaxis monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/bmt-tandem-meetings-or-ommited-doses-of-post-transplant-mtx-with-alternative-agents-as-gvhd-prophylaxis-a-retrospective-study monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/bmt-tandem-meetings-or-infliximab-with-or-without-extracorporeal-photopheresis-for-steroid-refractory-acute-gvhd monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/post-transplant-cyclophosphamide-for-gvhd-prophylaxis-in-unrelated-donor-sickle-cell-disease monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/interleukin-7-polymorphisms-as-predictors-of-gvhd-and-cmv monthly 0.9 2020-11-06T13:14:00.000Z https://gvhdhub.com/medical-information/dr-florent-malard-or-ash17-or-new-protocols-and-strategies-to-improve-patient-care-in-allo-transplant monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/prof-attilio-olivieri-or-ash-2017-or-prevention-of-acute-and-severe-gvhd monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/prof-arnon-nagler-or-ash-2017-or-the-promise-of-novel-treatments-in-immunosuppression monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/prof-ali-bazarbachi-or-ash-2017-or-novel-targeted-therapies-before-and-after-transplantation monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/prof-mohamad-mohty-or-introduction-to-the-gvhd-hub monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/medical-information/dr-steven-pavletic-or-ash-2017-or-t-and-b-cell-targeting-cellular-therapy-and-risk-stratification monthly 0.9 2022-07-04T12:42:00.000Z https://gvhdhub.com/about-us/louise-niven monthly 0.6 2026-03-10T10:35:00.000Z https://gvhdhub.com/about-us/helen-croxall-1 monthly 0.6 2026-03-10T10:35:00.000Z https://gvhdhub.com/about-us/jen-wilkinson monthly 0.6 2026-03-10T10:35:00.000Z https://gvhdhub.com/about-us/amelia-campbell-warner monthly 0.6 2026-03-10T10:35:00.000Z https://gvhdhub.com/about-us/jennifer-higgins monthly 0.6 2026-02-25T14:53:00.000Z https://gvhdhub.com/about-us/beth-campbell monthly 0.6 2026-03-10T10:35:00.000Z https://gvhdhub.com/about-us/haimanti-mandal monthly 0.6 2026-03-10T10:35:00.000Z https://gvhdhub.com/about-us/dylan-barrett monthly 0.6 2026-03-10T10:35:00.000Z https://gvhdhub.com/about-us/sari-cumming monthly 0.6 2026-03-10T10:35:00.000Z https://gvhdhub.com/about-us/devon-else monthly 0.6 2026-02-25T14:53:00.000Z https://gvhdhub.com/about-us/nathan-fisher monthly 0.6 2026-02-25T14:53:00.000Z https://gvhdhub.com/about-us/amy-hopkins monthly 0.6 2026-02-25T14:53:00.000Z https://gvhdhub.com/about-us/becky-gribbell monthly 0.6 2026-03-20T13:10:00.000Z https://gvhdhub.com/about-us/natasha-fort monthly 0.6 2026-02-25T14:53:00.000Z https://gvhdhub.com/about-us/addy-dullaghan monthly 0.6 2026-02-25T14:53:00.000Z https://gvhdhub.com/about-us/alison-roddam monthly 0.6 2026-02-25T14:53:00.000Z https://gvhdhub.com/about-us/monty-morris monthly 0.6 2026-04-02T14:42:00.000Z https://gvhdhub.com/about-us/abbie-mckillop monthly 0.6 2026-04-02T14:42:00.000Z https://gvhdhub.com/about-us/nathalie-tipler monthly 0.6 2026-04-02T14:42:00.000Z https://gvhdhub.com/about-us/suzanna-de-barra monthly 0.6 2026-04-02T14:42:00.000Z https://gvhdhub.com/about-us/chris-barnes monthly 0.6 2026-04-02T14:42:00.000Z https://gvhdhub.com/contributors/mohamad-mohty monthly 0.6 2025-04-24T09:06:00.000Z https://gvhdhub.com/contributors/ali-bazarbachi monthly 0.6 2025-04-24T09:15:00.000Z https://gvhdhub.com/contributors/arnon-nagler monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/attilio-olivieri monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/andrew-harris monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/daniel-wolff monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/corey-cutler monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/bipin-savani monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/florent-malard monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/frederic-baron monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/zinaida-peric monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/yi-bin-chen monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/takanori-teshima monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/robert-zeiser monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/steven-pavletic monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/amin-alousi monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/grzegorz-basak monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/hildegard-greinix monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/contributors/mutlu-arat monthly 0.6 2025-05-08T10:45:00.000Z https://gvhdhub.com/steering-committees monthly 0.7 2026-04-03T21:04:50.742Z https://gvhdhub.com/about-us monthly 0.7 2026-04-03T21:04:50.742Z https://gvhdhub.com/newsletter monthly 0.7 2026-04-03T21:04:50.742Z https://gvhdhub.com/our-hubs monthly 0.7 2026-04-03T21:04:50.742Z https://gvhdhub.com/contact monthly 0.7 2026-04-03T21:04:50.742Z